


=>

Uploading C:\Program Files\Stnexp\Queries\10522958-updated.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

L1 STRUCTURE UPLOADED

=> d his

(FILE 'HOME' ENTERED AT 21:59:26 ON 23 JAN 2008)

FILE 'REGISTRY' ENTERED AT 21:59:39 ON 23 JAN 2008

L1 STRUCTURE UPLOADED

L2 958 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 22:00:11 ON 23 JAN 2008

L3 37 S L2


L4 2 S US200!-522958/APPS

L5 1 S L3 AND L4

L6 36 S L3 NOT L4

FILE 'REGISTRY' ENTERED AT 22:00:46 ON 23 JAN 2008

>> Uploading C:\Program Files\Stnexp\Queries\10522958-updated.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14
exact/norm bonds :
5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5
isolated ring systems :
containing 1 : 10 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

L1 STRUCTURE UPLOADED

>> d his

(FILE 'HOME' ENTERED AT 21:59:26 ON 23 JAN 2008)

FILE 'REGISTRY' ENTERED AT 21:59:39 ON 23 JAN 2008

L1 STRUCTURE UPLOADED
L2 958 S L1 958 FULL

FILE 'CAPLUS' ENTERED AT 22:00:11 ON 23 JAN 2008


L3 37 S L2
L4 2 S US2001-522958/APPS
L5 1 S L3 AND L4
L6 36 S L3 NOT L4

FILE 'REGISTRY' ENTERED AT 22:00:46 ON 23 JAN 2008

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS ON STN
AN 2004:143141 CAPLUS [Full-text](#)

DN 140:199325
TI Preparation of benzimidazolyl substituted thiophenes as Polo like Kinases (PLK) inhibitors for treating cancer
IN Andrews, Clarence W., III; Cheung, Mui; Davis-Ward, Ronda G.; Drewry, David Harold; Emmette, Kyle Allen; Hubbard, Robert Dale; Kuntz, Kevin W.; Linn, James Andrew; Mook, Robert Anthony; Smith, Gary Keith; Veal, James Marvin
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014899	A1	20040219	WO 2003-024272	20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493908	A1	20040219	CA 2003-2493908	20030804
AU 2003265348	A1	20040225	AU 2003-265348	20030804
AU 2003265348	B2	20070816		
EP 1546137	A1	20050629	EP 2003-784888	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013160	A	20050712	BR 2003-13160	20030804
CN 1688576	A	20051026	CN 2003-823755	20030804
JP 20060505522	T	20060216	JP 2004-527723	20030804
NZ 539134	A	20060331	NZ 2003-539134	20030804
RU 2296758	C2	20070410	RU 2005-102390	20030804
ZA 2005000864	A	20060426	ZA 2005-864	20050128
NO 200500525	A	20050506	NO 2005-525	20050131
US 2006074119	A1	20060406	US 2005-522958	20050131
MX 2005PA01544	A	20050419	MX 2005-PA1544	20050209
IN 2005KN00321	A	20060106	IN 2005-KN321	20050302
PRAI US 2002-402008P	P	20020808		
WO 2003-024272	W	20030804		
OS MARPAT 140:199325				
GI				



AB The title compds. [I; R1 = H, alkyl, COR7, CO2R7, etc.; Q1 = OCH2Ph, NHCH2Ph (both substituted on Ph ring), etc.; n = 0-4; Q2 = OMe, Cl, Br, etc.; R5 = H, halo, alkyl, etc.; R7 = H, alkyl, cycloalkyl, etc.], useful for treating a condition mediated by PLK, were prepared. E.g., a multi-step synthesis of II which showed pIC50 of > 7 in assay for inhibition of PLK1, was given. The pharmaceutical composition comprising the title compds. I is claimed.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

>> d 16 tot bib abs hitstr

X L6 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2007:1420678 CAPLUS [Full-text](#)
DN 148:55071

TI Preparation of benzimidazolylthiophene benzyl ether compounds as PLK1 inhibitors

IN Kuntz, Kevin Wayne; Emerson, Holly Kathleen; Cheung, Mui; Badiang, Jennifer Gabriel

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 113pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO. (no US appl)	DATE
WO 2007143506	A2	20071213	WO 2007-US70108	20070531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2006-810315P	P	20060602 (not art)		
GI				



AB Title compds. represented by the formula I [wherein R1, R2 = independently H, halo, (halo)alkyl, etc.; R3 = H or alkyl; n = 0-2; R4 = independently halo, Y1 = O, (un)substituted amino, -CONH- or -NHCO-; R5 = alkylene; n = 1 or 2; R6 = independently OR7 or NR7R8; R7, R8 = independently H, (cyclo)alkyl, (cyclo)alkenyl or alkynyl; and pharmaceutically acceptable salts or solvates thereof] were prepared as polo-like kinase (PLK) 1 inhibitors for treatment of susceptible neoplasms. For example, II*HCO2H was provided in a multi-step synthesis starting from 2-chloro-3-nitrobenzaldehyde. I were tested for inhibition of PLK1 and cell proliferation by PLK1 inhibitors.


IT 959909-91-2P, 5-[5,6-Bis(methoxy)-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[2-chloro-5-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]ethoxy]-2-thiophenecarboxamide]formate] 959909-95-5P, 5-[5,6-Bis(methoxy)-1H-benzimidazol-1-yl]-3-[[[(1R)-1-[2-chloro-3-[[2-hydroxyethyl]amino]phenyl]ethoxy]-2-thiophenecarboxamide] 959910-55-0P, 3-[[[(1R)-1-[3-[[2-(2-aminoethyl)oxy]-2-chlorophenyl]ethoxy]-5-[5,6-bis(methoxy)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide] 959910-71-1P, 3-[[[(1R)-1-[3-[[2-(2-aminoethyl)oxy]-2-chlorophenyl]ethoxy]-5-[5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamide] 959910-72-2P, 3-[[[(1R)-1-[2-chloro-3-[[3-hydroxypropyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide] 959910-03-3P, 3-[[[(1R)-1-[2-chloro-3-[[2-hydroxyethyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide] 959910-04-4P, 3-[[[(1R)-1-[3-[[2-(2-aminoethyl)oxy]-2-chlorophenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide] 959910-05-5P, 3-[[[(1R)-1-[2-chloro-3-[[2-(dimethylamino)ethyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide] 959910-06-6P, 3-[[[(1R)-1-[2-chloro-3-[[3-(dimethylamino)propyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide] 959909-91-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 959909-90-1

CMF C27 H30 Cl NS O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=C-N-OH

RN 959909-95-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(2-hydroxyethyl)amino]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-99-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959910-01-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959910-02-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(3-hydroxypropoxy)phenyl]ethoxy]-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959910-03-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(2-hydroxyethoxy)phenyl]ethoxy]-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 959910-04-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● RC1

RN 959910-05-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(2-(dimethylamino)ethoxy)phenyl]ethoxy]-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-06-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(2-(dimethylamino)propoxy)phenyl]ethoxy]-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 113387-85-2, Methyl 5-(1H-benzimidazol-1-yl)-3-hydroxy-2-thiophenecarboxylate (66870-09-7), Methyl 5-[5,6-bis(methoxy)-1H-benzimidazol-1-yl]-3-hydroxy-2-thiophenecarboxylate

RL: RCT (Reactant), RACT (Reactant or reagent)

(preparation of 5-benzimidazolylthiophene-2-carboxamides as PLK1 inhibitors for treatment of neoplasms)


RN 113387-85-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 660870-09-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




IT 660870-06-4P, Methyl 5-(5-bromo-1H-benzimidazol-1-yl)-3-hydroxy-2-thiophenecarboxylate 959909-46-5P, Methyl 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(tert-butylidimethylsilyl)oxy]thiophene-2-carboxylate 929276-47-1P, Methyl 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(phenylmethyl)oxy]-2-thiophenecarboxylate 929280-84-2P, Methyl 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(phenylmethyl)oxy]-2-thiophenecarboxylate 929280-85-4P, Methyl 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxylate 929280-90-0P 959909-77-4P, Methyl 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(tert-butylidimethylsilyl)oxy]thiophene-2-carboxylate 959909-42-1P 959909-63-2P 959909-84-3P 959909-85-4P 959909-86-5P 959909-87-6P 959909-92-3P, Methyl 5-[5,6-bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[1-(2-chloro-5-iodophenyl)ethyl]oxy]-2-thiophenecarboxylate 959909-93-4P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[[R]-1-(2-chloro-5-iodophenyl)ethyl]oxy]-2-thiophenecarboxamide 959909-94-5P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[[1R]-1-(2-chloro-5-[[2,5-dioxo-1-pyrrolidinyl]oxy]carbonyl]phenyl]ethyl]oxy]-2-thiophenecarboxamide 959909-96-7P 959909-97-8P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[[1R]-1-(2-chloro-3-nitrophenyl)ethyl]oxy]-2-thiophenecarboxamide 959909-98-9P, 3-[[[1R]-1-(3-Amino-2-chlorophenyl)ethyl]oxy]-5-[5,6-bis(methyloxy)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide 959910-00-0P 959910-07-7P, 5-[5,6-Bis(methyloxy)-1H-benzimidazol-1-yl]-3-[[1-(2-chloro-5-iodophenyl)ethyl]oxy]-2-thiophenecarboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-benzimidazolythiophene-2-carboxamides as PLK1 inhibitors for treatment of neoplasms)

RN 660870-06-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 929095-46-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)


dimethylethyl)dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)




RN 929276-47-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929280-84-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 929280-85-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 929280-90-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

INDEX NAME)

Absolute stereochemistry.




RN 959909-77-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)



RN 959909-82-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-(2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-83-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[[[1R]-1-(2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-84-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-85-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-(2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-86-5 CAPLUS

10522958-updated

13 of 356

CN 2-Thiophenecarboxylic acid, 5-[(1H-benzimidazol-1-yl)-3-[(1R)-1-[(3-bromoethoxy)-2-chlorophenyl]ethoxy]-], methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-87-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[(1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-], methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-92-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[1-(2-chloro-5-iodophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)



RN 959909-93-4 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-5-iodophenyl)ethoxy]-5-(5,6-

10522958-updated

14 of 356

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-94-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959909-96-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-97-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-(5,6-

10522958-updated

15 of 356

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-98-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(3-amino-2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-00-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[(3-(2-bromoethoxy)-2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-], methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959910-07-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-(2-chloro-5-iodophenyl)ethoxy]-5-(5,6-

10522958-updated

16 of 356

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



X L6 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1420591 CAPLUS Full-text

DN 148:55070

TI Benzimidazole thiophene compounds and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Kuntz, Kevin; Emmitte, Kyle Allen; Rheault, Tara Renae; Smith, Stephen; Hornberger, Keith; Dickson, Hamilton; Cheung, Mui

PA SmithKline Beecham Corporation, USA

SO PCT Int. Appl., 303pp.

CODEM: PIXXD2

DT Patent

LA English

FAN: CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO. (no US case)	DATE
PI WO 2007:43456	A2	20071213	WO 2007-US69879	20070529
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TW				
PRAI US 2006-810526P	P	20060602	(not prior art)	

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides benzimidazolylthiophene compds. of formula I, pharmaceutical compns. containing the same, processes for preparing the same and their use as pharmaceutical agents. Compds. of formula I wherein R1 and R2 are independently H, halo, (halo)alkyl, OH and derivs., CN, CONH2 and

deriva., etc., R3 and each R4 are independently H, and (halo)alkyl; Z1, Z2 and Z3 are independently C, CH, and N, provided that at least one of Z1, Z2 and Z3 is C or CH; d is 0, 1 and 2; Y1 is O and NH and deriva., a is 0 and 1; each R5 is independently C1-3 alkylene; A is 5- to 6-membered heterocyclic ring; b is 0, 1 and 2; each R6 is halo, (haloalkyl)alkenyl, CN, R5-CN, CO2H and deriva., CONH2 and deriva., etc., and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their PLK1 and HCT116 inhibitory activity. From the assay it was determined that compound II exhibited IC50 values of < 0.5 μ M.


IT 959998-35-7P 959998-78-8P 959998-80-2P
959998-66-8P 959998-89-1P 959998-93-7P
959998-95-7P 959998-99-3P 959998-04-3P
959998-07-6P 959998-37-2P 959998-35-4P
959998-41-8P 959998-42-0P 959998-43-2P
959998-49-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate and intermediate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)

RN 959998-35-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-78-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-80-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-96-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



PAGE 1-A



RN 959998-89-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 959998-88-0

PAGE 1-B

CMF C30 H31 C1 N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 959998-93-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




PAGE 1-A



RN 959998-95-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-99-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-04-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-07-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-37-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 959999-39-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 959999-49-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




IT 959999-49-6
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)


RN 959999-35-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 959999-41-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 959999-43-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 959999-45-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[[3-(4-piperidin-4-yl)oxy]phenyl]methoxy]- (CA INDEX NAME)


959999-45-2 959999-46-2 959999-47-2 959999-48-2 959999-49-2 959999-50-2 959999-51-2 959999-52-2 959999-53-2 959999-54-2 959999-55-2 959999-56-2 959999-57-2 959999-58-2 959999-59-2 959999-60-2 959999-61-2 959999-62-2 959999-63-2 959999-64-2 959999-65-2 959999-66-2 959999-67-2 959999-68-2 959999-69-2 959999-70-2 959999-71-2 959999-72-2 959999-73-2 959999-74-2 959999-75-2 959999-76-2 959999-77-2 959999-78-2 959999-79-2 959999-80-2 959999-81-2 959999-82-2 959999-83-2 959999-84-2 959999-85-2 959999-86-2 959999-87-2 959999-88-2 959999-89-2 959999-90-2 959999-91-2 959999-92-2 959999-93-2 959999-94-2 959999-95-2 959999-96-2 959999-97-2 959999-98-2 959999-99-2

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)

RN 959999-94-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-96-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidin-4-yl)methyl]amino]phenyl]ethoxy]-5-[5,6-dimethoxy-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

25 of 356




RN 959997-98-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-00-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-02-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


10522958-updated

27 of 356




RN 959998-10-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-12-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(6-methyl-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959998-14-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-


10522958-updated

26 of 356




RN 959998-04-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 959998-06-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-08-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10522958-updated

28 of 356


piperidinyl)oxy]phenyl]ethoxy]-5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-16-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-18-6 CAPLUS
CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-20-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.





RN 959998-23-3 CAPLUS
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-((1R)-1-(2-chloro-3-(2-(4-morpholinyl)ethoxy)phenyl)ethoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-25-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-((1R)-1-(2-chloro-3-(2-(1-piperazinyl)ethoxy)phenyl)ethoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-31-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-33-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-37-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


RN 959998-27-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-((1R)-1-(2-chloro-3-(2-(4-methyl-1-piperazinyl)ethoxy)phenyl)ethoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-29-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




PAGE 1-A

Absolute stereochemistry.




RN 959998-39-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-41-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-42-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-((1R)-1-(2-chloro-3-(2-(4-morpholinyl)ethoxy)phenyl)ethoxy)-5-((1-methyl-1H-pyrazol-4-yl)-1H-

Absolute stereochemistry.




RN 959998-44-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-47-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-49-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B


CP3

RN 959998-58-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




PAGE 1-A



RN 959998-52-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-(2-fluoroethyl)-4-piperidinyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

CH2P

RN 959998-55-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


RN 959998-61-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959998-63-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959998-67-5 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-4-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 959998-66-4

CMF C10 H30 Cl1 F1 N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 959998-70-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-4-fluoro-3-[(1-(2-fluoroethyl)-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CH2F

RN 959998-72-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 959998-74-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959998-76-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-6-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959998-82-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)methoxy]phenyl]ethoxy]-5-[5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959998-84-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]ethoxy]-5-[5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959998-91-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)methoxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Me

RN 959998-97-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-01-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-03-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-05-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-08-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-11-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-14-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-17-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-19-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-20-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-21-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

10522958-updated


45 of 356



RN 959999-23-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(trifluoromethoxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-25-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-26-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(6-(trifluoromethoxy)-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


46 of 356



RN 959999-27-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-28-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(5,6-difluoro-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-29-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

10522958-updated


47 of 356



RN 959999-30-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-31-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-32-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]- (CA INDEX NAME)

10522958-updated

48 of 356


Absolute stereochemistry.



RN 959999-33-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-34-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 959999-36-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 959999-38-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-[2-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 959999-40-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 959999-42-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 959999-44-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 959999-46-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3-[(1-methyl-4-piperidinyl)oxy]phenyl]methoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]]- (CA INDEX NAME)




RN 959999-47-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 959999-48-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 959999-50-9 CAPLUS

CN 3-3-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




1T 660853-39-8P 660870-05-3P 660870-04-4P
660870-07-5P 660370-08-6P 929095-38-5P
929095-33-6P 929095-46-5P 929095-62-5P
929095-63-6P 929095-64-7P 929276-47-1P
929280-84-2P 929220-86-4P 929286-50-0P

959909-77-1P	959909-82-1P	959909-83-2P
959909-78-1P	959909-85-4P	959909-86-6P
959909-87-6P	959909-96-7P	959909-97-9P
959909-98-9P	959909-100-0P	959909-102-0P
959909-51-1P	959909-53-2P	959909-54-3P
959909-55-4P	959909-56-5P	959909-57-6P
959909-58-7P	959909-59-8P	959909-60-1P
959909-61-2P	959909-62-2P	959909-63-3P
959909-70-1P	959909-71-4P	959909-72-6P
959909-76-3P	959909-77-0P	959909-78-1P
959909-79-2P	959909-80-3P	959909-82-0P
959909-83-2P	959909-85-7P	959909-86-8P
959909-87-2P	959909-88-2P	959909-90-7P
959909-91-8P	959909-92-5P	959909-93-0P
959909-94-1P	959909-95-2P	959909-97-4P
959909-59-6P	959909-61-5P	959909-03-7P
959909-05-2P	959909-07-1P	959909-09-3P
959909-10-6P	959909-11-7P	959909-12-8P
959909-14-0P	959909-16-2P	959909-18-4P
959909-19-5P	959909-20-8P	959909-22-3P
959909-24-2P	959909-26-4P	959909-28-6P
959909-29-7P	959909-30-0P	959909-32-2P
959909-33-3P	959909-35-5P	959909-37-7P
959909-38-2P	959909-40-1P	959909-42-8P
959909-42-4P	959909-43-5P	959909-44-6P
959909-44-4P	959909-47-9P	959909-48-0P
959909-50-4P	959909-52-6P	959909-53-7P
959909-55-5P	959909-56-0P	959909-58-2P
959909-57-2P	959909-60-6P	959909-61-7P
959909-62-8P	959909-63-5P	959909-64-0P
959909-65-1P	959909-66-2P	959909-67-3P
959909-69-4P	959909-69-5P	959909-70-8P
959909-71-9P	959909-72-0P	959909-73-1P
959909-74-2P	959909-75-3P	959909-76-4P
959909-79-5P	959909-78-6P	959909-79-7P
959909-80-1P	959909-81-4P	959909-82-5P
959909-83-3P	959909-84-4P	959909-85-5P
959909-86-6P	959909-87-7P	959909-88-8P
959909-89-9P	959909-90-2P	959909-91-3P
959909-92-4P	959909-94-6P	959909-96-8P
959909-97-9P	959909-98-0P	959909-01-5P
959909-02-9P	959909-03-0P	959909-04-1P
959909-05-2P	959909-06-3P	959909-10-9P
959909-11-0P	959909-17-6P	959909-12-7P
959909-24-5P	959909-25-6P	959909-31-6P
959909-32-5P	959909-37-0P	959909-38-1P
959909-39-2P	959909-40-5P	959909-43-6P
959909-43-4P	959909-45-1P	959909-47-8P
959909-48-1P	959909-50-7P	959909-51-6P
959909-53-9P	959909-55-2P	959909-60-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)

RN 660869-99-8 CAPLUS


2-Thiophenecarboxylic acid, 5-(5-chloro-1H-benzimidazol-1-yl)-3-hydroxy-,
methyl ester (CA INDEX NAME)




RN 660870-00-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-chloro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 660870-06-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 660870-07-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 660870-08-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5,6-dichloro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 929095-38-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-39-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-46-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(1,1-dimethylethyl)dimethylsilyloxy]-, methyl ester (CA INDEX NAME)




RN 929095-62-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-63-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 929276-47-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929280-84-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 929280-86-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 929280-90-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959909-77-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-([(1,1-dimethylethyl)dimethylsilyl]oxy)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)



RN 959909-82-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-([(1R)-1-[2-chloro-3-([(1,1-dimethylethyl)dimethylsilyl]oxy)phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-83-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-([(1R)-1-[2-

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-([(1R)-1-[3-(2-bromoethoxy)-2-chlorophenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-87-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-([(1R)-1-[2-chloro-3-hydroxyphenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-96-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-([(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959909-97-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-([(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-(5,6-

chloro-3-([(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-84-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-([(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-85-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-([(1R)-1-[2-chloro-3-([(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-86-5 CAPLUS

dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959909-98-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-([(1R)-1-(3-amino-2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959910-00-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-([(1R)-1-[3-(2-bromoethoxy)-2-chlorophenyl]ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-51-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-chloro-1H-benzimidazol-1-yl)-3-([(1R)-1-(2-

10522958-updated 61 of 356
chloro-3-hydroxyphenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-52-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-chloro-1H-benzimidazol-1-yl)-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester (CA INDEX NAME)




RN 959999-53-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-54-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-cyano-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)

10522958-updated 62 of 356




RN 959999-55-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-cyano-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 959999-56-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-cyano-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-57-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

10522958-updated 63 of 356




RN 959999-58-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 959999-59-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-60-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(6-methyl-3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

10522958-updated 64 of 356




RN 959999-61-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-62-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959999-63-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-70-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 959999-71-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-chloro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 959999-79-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 959999-80-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-82-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

RN 959999-72-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(6-chloro-1H-benzimidazol-1-yl)-3-[(1,1-dimethylethyl)dimethylsilyloxy]-, methyl ester (CA INDEX NAME)



RN 959999-76-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 959999-77-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-78-1 CAPLUS



RN 959999-83-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-[(1,1-dimethylethyl)dimethylsilyloxy]phenyl)ethoxy]-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-84-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5,6-difluoro-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-85-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5,6-difluoro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 959999-87-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[(1R)-1-[[5-(5-bromo-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-88-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-90-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-hydroxy-5-(methoxycarbonyl)-2-thienyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 959999-91-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-, 2-propen-1-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-92-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-(6-cyano-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-93-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[5-(6-cyano-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-94-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 959999-95-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(6-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 959999-97-4 CAPLUS


RN 959999-96-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[(1R)-1-[[5-(6-bromo-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 959999-99-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 960000-01-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[5-(5-chloro-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

RN 960000-03-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

-OBu-t

RN 960000-07-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A



RN 960000-05-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[(5-(6-methyl-3-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl)oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




-OBu-t

RN 960000-09-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 960000-11-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-10-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[(3-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl)oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


RN 960000-12-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[(1H-benzimidazol-1-yl)-3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-14-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-{3-[(1R)-1-[[5-(1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-16-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-18-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-{1H-benzimidazol-1-yl}-3-[(1R)-1-[2-chloro-3-[2-(4-morpholinyl)ethoxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 960000-24-2 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-26-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-19-5 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-{3-[(1R)-1-[[5-(1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]-2-chlorophenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-20-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-22-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-{1H-benzimidazol-1-yl}-3-[(1R)-1-[2-chloro-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]ethoxy]-, methyl ester (CA INDEX NAME)




RN 960000-28-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-29-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



10522958-updated 81 of 356


RN 960000-30-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-32-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 960000-33-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-35-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[3-(2-bromoethoxy)-2-

10522958-updated 83 of 356


RN 960000-40-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 960000-41-3 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-[(2-chloro-3-[(1R)-1-[5-(5-chloro-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-42-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

10522958-updated 82 of 356


chlorophenylethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-37-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[2-(4-morpholinyl)ethoxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-39-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[3-(2-bromoethoxy)-2-chlorophenyl]ethoxy]-5-[5-(5-chloro-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated 84 of 356

RN 960000-43-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[[1-(2-fluoroethyl)-4-piperidinyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

CH2F

RN 960000-44-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 960000-46-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-chloro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-4-fluoro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000 47-9 CAPLUS



RN 960000-52-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-53-7 CAPLUS

2-Thiophenecarboxylic acid, 3-{(1R)-1-[2-chloro-4-fluoro-3-{(1-methyl-4-piperidinyl)oxy}phenyl]ethoxy}-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-4B-0 CAPLUS

2-Thiophenecarboxylic acid, 3-((1R)-1-(2-chloro-4-fluoro-3-hydroxyphenyl)ethoxy)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-50-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-6-fluoro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxyethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-55-9 CAPLUS


3-2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-4-fluoro-3-[[1-(2-fluoroethyl)-4-piperidinyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-56-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-58-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-59-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




— OBU-t

RN 960000-60-6 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[1-(2-chloro-6-fluoro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-61-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[1-(2-chloro-6-fluoro-3-[(1-methyl-4-piperidinyl)oxy]phenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-62-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[2-chloro-3-[(1R)-1-[[5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-63-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]ethoxy]-5-[5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)]

Absolute stereochemistry.



RN 960000-64-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




— OBU-t

RN 960000-65-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B

-OBu-t

RN 960000-66-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-70-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[5-(6-chloro-1H-benzimidazol-1-yl)-2-(methoxycarbonyl)-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-71-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960000-72-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 960000-67-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-68-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-69-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-OBu-t

RN 960000-73-1 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-74-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 960000-75-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(methylthio)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-76-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[6-(methylthio)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-77-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(methylthio)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 960000-78-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-(methylthio)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 960000-79-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 960000-80-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 960000-81-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-82-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960000-83-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-84-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-85-5 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960000-86-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[1R]-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-87-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[[[1R]-1-[[2-(methoxycarbonyl)-5-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-88-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



Absolute stereochemistry.



RN 960000-89-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-94-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy], methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960000-96-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 960000-97-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 960000-90-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 960000-91-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[2-(methoxycarbonyl)-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-92-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl]ethoxy]-5-[5-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960000-98-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960001-01-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 960001-02-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 960001-03-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-fluoro-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 960001-04-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 960001-05-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 960001-06-3 CAPLUS




RN 960001-18-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 960001-24-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-{[4-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-2-pyrimidinyl]oxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 960001-25-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-(5,6-dichloro-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 960001-10-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 960001-11-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 960001-17-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-{[2-fluoro-3-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 960001-31-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-{[4-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-2-pyridinyl]oxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 960001-32-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 960001-37-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-{[6-{1-[[2-(methoxycarbonyl)-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-2-pyridinyl]oxy}-, 1,1-dimethylethyl ester (CA INDEX NAME)

10522958-updated


109 of 356



RN 960001-39-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 960001-39-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[[2-(methoxycarbonyl)-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]methyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 960001-40-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

10522958-updated


110 of 356



RN 960001-43-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-[[1-[[2-(methoxycarbonyl)-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]-4-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 960001-44-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 960001-45-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-, 2-acetylhydrazide (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

111 of 356




RN 960001-47-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960001-49-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 960001-50-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

112 of 356




RN 960001-51-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 960001-53-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-chloro-3-[(1R)-1-[[[2-(methoxycarbonyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-benzimidazol-1-yl]-3-thienyl]oxy]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



Absolute stereochemistry.




—OBu-t

RN 960001-55-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



IT 113387-85-2, Methyl 5-(1H-benzimidazol-1-yl)-3-hydroxy-thiophene-2-carboxylate 660870-09-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)
RN 113387-85-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 660870-09-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)




X L6 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:819365 CAPLUS Full-text
DN 147:359215
TI Pharmacological and Functional Comparison of the Polo-like Kinase Family: Insight into Inhibitor and Substrate Specificity
AU Johnson, Eric F.; Stewart, Kent D.; Woods, Keith M.; Giranda, Vincent L.; Luo, Yan
CS Cancer Research, Abbott Laboratories, Abbott Park, IL, 60064, USA

—OBu-t

RN 960002-40-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[6-(trifluoromethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



IT 960001-63-2F
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prophetic intermediate; preparation of benzimidazolylthiophene compds. useful in treatment of diseases)
RN 960001-63-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-chloro-3-[(1,1-dimethylethyl)diphenylsilyloxy]-6-fluorophenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

SO Biochemistry (2007), 46(33), 9551-9563 - NOT ODP/NOT PRIOR ART
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
AB PLK1 (polo-like kinase 1) is a key mitotic kinase and a therapeutic target in the treatment of proliferative diseases. Here we investigate the relative substrate specificity and pharmacol. relatedness of PLK1, -2, -3, and -4 that together comprise a conserved family of Ser/Thr kinases (PLK family). We report consensus substrate sequences for PLK2, -3, and -4 and an expanded consensus sequence for PLK1, which we use to design an optimal peptide substrate, PLKtide. We report inhibitory activity for the entire PLK family across a diverse set of small-mol. ATP-competitive inhibitors including several clin. compds. With respect to both substrate and ATP-site specificity, highest similarity is observed between PLK2 and PLK3, PLK1 is next most similar, and PLK4 is least similar. Further, we have identified and report time-dependent inhibition by two potent and selective PLK inhibitors.
IT 660868-91-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(insight into inhibitor and substrate specificity of polo-like kinase family)
RN 660868-91-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)



RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:284227 CAPLUS Full-text
DN 146:337892
TI Regioselective process for preparing benzimidazole thiophenes
IN Hornberger, Keith; Cheung, Mui; Pobanz, Mark Andrew; Emmite, Kyle Allen; Kuntz, Kevin Wayne; Badiang, Jennifer Gabriel
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 31pp.
CODEN: PIXAD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
(NOT ODP)
PI WO 2007030366 A1 20070315 WO 2006-083793 20060828



M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MM, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRA1 US 2005-714301P P 20050906 - NOT PRIOR ART

OS MARPAT 146:337892


GI



AB The present invention provides a process for preparing benzimidazole thiophene compds. of formula 1 [R1 = H, alkyl, alkenyl, etc.; Q1 = -(R2)a(Y1)b(R2)cR3; a, b and c independently = 0 or 1 and at least one of a or b = 1; n = 0-3; each Q2 independently = -(R2)aa(Y2)bb(R2)ccR4; or two adjacent Q2 together form a cyclic or heterocyclic ring optionally substituted; aa, bb and cc independently = 0 or 1; each Y1 and Y2 independently = O, CO, CO2, etc.; each R2 independently = alkylene, alkenylene and alkynylene; each R3 and R4 independently = H, halo, alkynyl, etc.; R5 = H, halo, cycloalkyl, etc.]. Thus, e.g., 11 was prepared by substitution of 2-bromo-4-((4-(methyloxy)phenyl)methyl)oxy)-1-nitrobenzene (preparation given) with Me 5-amino-3-((1R)-1-[2-(trifluoromethyl)phenyl]ethyl)oxy)-2-thiophene carboxylate (preparation given) followed by nitro group reduction, cyclization with tri-Me orthoformate to form benzimidazole core, and deprotection. The processes of the instant invention produce the desired regioisomer via a more direct and efficient route, utilizing less resources and leading to a better yield. Intermediates used in the process are also claimed. Pharmaceutical compns. and therapeutic uses for 1 were described in prior patent (PCT Publication NO. WO04/014899; published 19 Feb. 2004).

IT 5: 179 5: 25 5: 25 179: 55-2F

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (regioselective process for preparing benzimidazole thiophenes)



IT 112377 55 2P 440882 51-2F 429040-09 5P

929040-11 3P 929040-24 4P 929040-25 5P

929040-26 4P 929040-27 5P 929040-28 6P

929040-29 6P 929040-30 7P 929040-31 8P

929040-32 8P 929040-33 9P 929040-34 10P

929040-35 10P 929040-36 11P 929040-37 12P

929040-38 12P 929040-39 13P 929040-40 14P

929040-41 14P 929040-42 15P 929040-43 16P

929040-44 16P 929040-45 17P 929040-46 18P

929040-47 18P 929040-48 19P 929040-49 20P

929040-50 20P 929040-51 21P 929040-52 22P

929040-53 22P 929040-54 23P 929040-55 24P

929040-56 24P 929040-57 25P 929040-58 26P

929040-59 26P 929040-60 27P 929040-61 28P

929040-62 28P 929040-63 29P 929040-64 30P

929040-65 30P 929040-66 31P 929040-67 32P

929040-68 32P 929040-69 33P 929040-70 34P

929040-71 34P 929040-72 35P 929040-73 36P

929040-74 36P 929040-75 37P 929040-76 38P

929040-77 38P 929040-78 39P 929040-79 40P

929040-80 40P 929040-81 41P 929040-82 42P

929040-83 42P 929040-84 43P 929040-85 44P

929040-86 44P 929040-87 45P 929040-88 46P

929040-89 46P 929040-90 47P 929040-91 48P

929040-92 48P 929040-93 49P 929040-94 50P

929040-95 50P 929040-96 51P 929040-97 52P

929040-98 52P 929040-99 53P 929040-100 54P

929040-101 54P 929040-102 55P 929040-103 56P

929040-104 56P 929040-105 57P 929040-106 58P

929040-107 58P 929040-108 59P 929040-109 60P

929040-110 60P 929040-111 61P 929040-112 62P

929040-113 62P 929040-114 63P 929040-115 64P

929040-116 64P 929040-117 65P 929040-118 66P

929040-119 66P 929040-120 67P 929040-121 68P

929040-122 68P 929040-123 69P 929040-124 70P

929040-125 70P 929040-126 71P 929040-127 72P

929040-128 72P 929040-129 73P 929040-130 74P

929040-131 74P 929040-132 75P 929040-133 76P

929040-134 76P 929040-135 77P 929040-136 78P

929040-137 78P 929040-138 79P 929040-139 80P

929040-140 80P 929040-141 81P 929040-142 82P

929040-143 82P 929040-144 83P 929040-145 84P

929040-146 84P 929040-147 85P 929040-148 86P

929040-149 86P 929040-150 87P 929040-151 88P

929040-152 88P 929040-153 89P 929040-154 90P

929040-155 90P 929040-156 91P 929040-157 92P

929040-158 92P 929040-159 93P 929040-160 94P

929040-161 94P 929040-162 95P 929040-163 96P

929040-164 96P 929040-165 97P 929040-166 98P

929040-167 98P 929040-168 99P 929040-169 100P

929040-170 100P 929040-171 101P 929040-172 102P

929040-173 102P 929040-174 103P 929040-175 104P

929040-176 104P 929040-177 105P 929040-178 106P

929040-179 106P 929040-180 107P 929040-181 108P

929040-182 108P 929040-183 109P 929040-184 110P

929040-185 110P 929040-186 111P 929040-187 112P

929040-188 112P 929040-189 113P 929040-190 114P

929040-191 114P 929040-192 115P 929040-193 116P

929040-194 116P 929040-195 117P 929040-196 118P

929040-197 118P 929040-198 119P 929040-199 120P

929040-200 120P 929040-201 121P 929040-202 122P

929040-203 122P 929040-204 123P 929040-205 124P

929040-206 124P 929040-207 125P 929040-208 126P

929040-209 126P 929040-210 127P 929040-211 128P

929040-212 128P 929040-213 129P 929040-214 130P

929040-215 130P 929040-216 131P 929040-217 132P

929040-218 132P 929040-219 133P 929040-220 134P

929040-221 134P 929040-222 135P 929040-223 136P

929040-224 136P 929040-225 137P 929040-226 138P

929040-227 138P 929040-228 139P 929040-229 140P

929040-230 140P 929040-231 141P 929040-232 142P

929040-233 142P 929040-234 143P 929040-235 144P

929040-236 144P 929040-237 145P 929040-238 146P

929040-239 146P 929040-240 147P 929040-241 148P

929040-242 148P 929040-243 149P 929040-244 150P

929040-245 150P 929040-246 151P 929040-247 152P

929040-248 152P 929040-249 153P 929040-250 154P

929040-251 154P 929040-252 155P 929040-253 156P

929040-254 156P 929040-255 157P 929040-256 158P

929040-257 158P 929040-258 159P 929040-259 160P

929040-260 160P 929040-261 161P 929040-262 162P

929040-263 162P 929040-264 163P 929040-265 164P

929040-266 164P 929040-267 165P 929040-268 166P

929040-269 166P 929040-270 167P 929040-271 168P

929040-272 168P 929040-273 169P 929040-274 170P

929040-275 170P 929040-276 171P 929040-277 172P

929040-278 172P 929040-279 173P 929040-280 174P

929040-281 174P 929040-282 175P 929040-283 176P

929040-284 176P 929040-285 177P 929040-286 178P

929040-287 178P 929040-288 179P 929040-289 180P

929040-290 180P 929040-291 181P 929040-292 182P

929040-293 182P 929040-294 183P 929040-295 184P

929040-296 184P 929040-297 185P 929040-298 186P

929040-299 186P 929040-300 187P 929040-301 188P

929040-302 188P 929040-303 189P 929040-304 190P

929040-305 190P 929040-306 191P 929040-307 192P

929040-308 192P 929040-309 193P 929040-310 194P

929040-311 194P 929040-312 195P 929040-313 196P

929040-314 196P 929040-315 197P 929040-316 198P

929040-317 198P 929040-318 199P 929040-319 200P

929040-320 200P 929040-321 201P 929040-322 202P

929040-323 202P 929040-324 203P 929040-325 204P

929040-326 204P 929040-327 205P 929040-328 206P

929040-329 206P 929040-330 207P 929040-331 208P

929040-332 208P 929040-333 209P 929040-334 210P

929040-335 210P 929040-336 211P 929040-337 212P

929040-338 212P 929040-339 213P 929040-340 214P

929040-341 214P 929040-342 215P 929040-343 216P

929040-344 216P 929040-345 217P 929040-346 218P

929040-347 218P 929040-348 219P 929040-349 220P

929040-350 220P 929040-351 221P 929040-352 222P

929040-353 222P 929040-354 223P 929040-355 224P

929040-356 224P 929040-357 225P 929040-358 226P

929040-359 226P 929040-360 227P 929040-361 228P

929040-362 228P 929040-363 229P 929040-364 230P

929040-365 230P 929040-366 231P 929040-367 232P

929040-368 232P 929040-369 233P 929040-370 234P

929040-371 234P 929040-372 235P 929040-373 236P

929040-374 236P 929040-375 237P 929040-376 238P

929040-377 238P 929040-378 239P 929040-379 240P

929040-380 240P 929040-381 241P 929040-382 242P

929040-383 242P 929040-384 243P 929040-385 244P

929040-386 244P 929040-387 245P 929040-388 246P

929040-389 246P 929040-390 247P 929040-391 248P

929040-392 248P 929040-393 249P 929040-394 250P

929040-395 250P 929040-396 251P 929040-397 252P

929040-398 252P 929040-399 253P 929040-400 254P

929040-401 254P 929040-402 255P 929040-403 256P

929040-404 256P 929040-405 257P 929040-406 258P

929040-407 258P 929040-408 259P 929040-409 260P

929040-410 260P 929040-411 261P 929040-412 262P

929040-413 262P 929040-414 263P 929040-415 264P

929040-416 264P 929040-417 265P 929040-418 266P

929040-419 266P 929040-420 267P 929040-421 268P

929040-422 268P 929040-423 269P 929040-424 270P

929040-425 270P 929040-426 271P 929040-427 272P

929040-428 272P 929040-429 273P 929040-430 274P

929040-431 274P 929040-432 275P 929040-433 276P

929040-434 276P 929040-435 277P 929040-436 278P

929040-437 278P 929040-438 279P 929040-439 280P

929040-440 280P 929040-441 281P 929040-442 282P

929040-443 282P 929040-444 283P 929040-445 284P

929040-446 284P 929040-447 285P 929040-448 286P

929040-449 286P 929040-450 287P 929040-451 288P

929040-452 288P 929040-453 289P 929040-454 290P

929040-455 290P 929040-456 291P 929040-457 292P

929040-458 292P 929040-459 293P 929040-460 294P

929040-461 294P 929040-462 295P 929040-463 296P

929040-464 296P 929040-465 297P 929040-466 298P

929040-467 298P 929040-468 299P 929040-469 300P

929040-470 300P 929040-471 301P 929040-472 302P

929040-473 302P 929040-474 303P 929040-475 304P

929040-476 304P 929040-477 305P 929040-478 306P

929040-479 306P 929040-480 307P 929040-481 308P

929040-482 308P 929040-483 309P 929040-484 310P

929040-485 310P 929040-486 311P 929040-487 312P

929040-488 312P 929040-489 313P 929040-490 314P

929040-491 314P 929040-492 315P 929040-493 316P

929040-494 316P 929040-495 317P 929040-496 318P

929040-497 318P 929040-498 319P 929040-499 320P

929040-500 320P 929040-501 321P 929040-502 322P

929040-503 322P 929040-504 323P 929040-505 324P

929040-506 324P 929040-507 325P 929040-508 326P

929040-509 326P 929040-510 327P 929040-511 328P

929040-512 328P 929040-513 329P 929040-514 330P

929040-515 330P 929040-516 331P 929040-517 332P

929040-518 332P 929040-519 333P 929040-520 334P

929040-521 334P 929040-522 335P 929040-523 336P

929040-524 336P 929040-525 337P 929040-526 338P

929040-527 338P 929040-528 339P 929040-529 340P

929040-530 340P 929040-531 341P 929040-532 342P

929040-533 342P 929040-534 343P 929040-535 344P

929040-536 344P 929040-537 345P 929040-538 346P

929040-539 346P 929040-540 347P 929040-541 348P

929040-542 348P 929040-543 349P 929040-544 350P

929040-545 350P 929040-546 351P 929040-547 352P

929040-548 352P 929040-549 353P 929040-550 354P

929040-551 354P 929040-552 355P 929040-553 356P

929040-554 356P 929040-555 357P 929040-556 358P

929040-557 358P 929040-558 359P 929040-559 360P

929040-560 360P 929040-561 361P 929040-562 362P

929040-563 362P 929040-564 363P 929040-565 364P

929040-566 364P 929040-567 365P 929040-568 366P

929040-569 366P 929040-570 367P 929040-571 368P

929040-572 368P 929040-573 369P 929040-574 370P

929040-575 370P 929040-576 371P 929040-577 372P

929040-578 372P 929040-579 373P 929040-580 374P

929040-581 374P 929040-582 375P 929040-583 376P

929040-584 376P 929040-585 377P 929040-586 378P

929040-587 378P 929040-588 379P 929040-589 380P

929040-590 380P 929040-591 381P 929040-592 382P

929040-593 382P 929040-594 383P 929040-595 384P

929040-596 384P 929040-597 385P 929040-598 386P

929040-599 386P 929040-600 387P 929040-601 388P

929040-602 388P 929040-603 389P 929040-604 390P

929040-605 390P 929040-606 391P 929040-607 392P

929040-608 392P 929040-609 393P 929040-610 394P

929040-611 394P 929040-612 395P 929040-613 396P

929040-614 396P 929040-615 397P 929040-616 398P

929040-617 398P 929040-618 399P 929040-619 400P

929040-620 400P 929040-621 401P 929040-622 402P

929040-623 402P 929040-624 403P 929040-625 404P

929040-626 404P 929040-627 405P 929040-628 406P

929040-629 406P 929040-630 407P 929040-631 408P


929040-632 408P 929040-633 409P 929040-634 410P

929040-635 410P 929040-636 411P 929040-637 412P

929040-638 412P 929040

10522958-updated


121 of 356



RN 929040-11-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-14-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


122 of 356



RN 929040-18-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-21-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

123 of 356

RN 929040-24-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-25-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[2-[(diphenylmethylene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-26-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


124 of 356



RN 929040-28-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-32-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-33-5 CAPLUS

10522958-updated

125 of 356

CN 2-Thiophenecarboxamide, 5-[(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-37-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-38-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


126 of 356



RN 929040-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-41-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


127 of 356



RN 929095-16-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-38-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-39-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

10522958-updated

128 of 356


Absolute stereochemistry.



RN 929095-41-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-42-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-43-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-48-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-ethenyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-49-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(1,2-dihydroxyethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-5-[6-[(trifluoromethyl)sulfonyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-59-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(dimethoxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-62-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-50-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-51-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-63-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-66-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-67-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(6-hydroxy-

Absolute stereochemistry.





RN 929095-71-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-74-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(methoxycarbonyl)-4-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-78-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929095-79-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-44-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.


RN 929095-75-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-[(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-76-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-77-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-47-1 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929276-48-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1-[4-hydroxy-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 929276-91-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(difluoro-4-piperidinylmethyl)-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CH 1

CRN 929276-90-4
CMF C26 H25 Cl F2 N4 O2 S

10522958-updated

137 of 356

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 929277-03-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[(1-oxido-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-1H-benzimidazol-1-yl]-1H-benzimidazol-1-yl]-1H-benzimidazol-1-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-09-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2,3-dihydroxypropyl)-1H-benzimidazol-1-yl]-1H-benzimidazol-1-yl (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated

139 of 356



RN 929277-58-7 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[(2-aminoethyl)methylamino]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)]

CM 1

CRN 929277-57-6

CMF C24 H26 Cl N5 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 929277-69-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinylmethyl)-1H-benzimidazol-1-yl]-1H-benzimidazol-1-yl (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


138 of 356



RN 929277-10-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[2-(1,3-dioxolan-2-yl)ethyl]-1H-benzimidazol-1-yl]-1H-benzimidazol-1-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-11-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(3-oxopropyl)-1H-benzimidazol-1-yl]-1H-benzimidazol-1-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-38-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-1H-benzimidazol-1-yl (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated

140 of 356



RN 929278-32-0 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3S)-3-piperidinylmethyl]-1H-benzimidazol-1-yl]-2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)]

CM 1

CRN 929278-31-9

CMF C26 H27 Cl N4 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 929278-54-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-1H-benzimidazol-1-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-56-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(4,4,5,5-tetramethyl-1,3,2 dioxaborolan-2-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-73-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(methoxycarbonyl)-4-[2-(trimethylsilyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 929278-95-5 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-97-7 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-04-9 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[3-[[[1,1-dimethylethyl]diphenylsilyl]oxy]-1-[2-[[[1,1-dimethylethyl]diphenylsilyl]oxy]ethyl]propoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 929278-78-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-ethyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-81-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 929278-83-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-06-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[3-hydroxy-1-(2-hydroxyethyl)propoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-08-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[3-chloro-1-(2-chloroethyl)propoxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-10-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-

10522958-updated

145 of 356

cyclopentyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-12-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[3-hydroxy-1-(2-hydroxyethyl)propoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-13-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(7-bromo-6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-15-2 CAPLUS

10522958-updated


147 of 356



RN 929279-21-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-7-bromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-23-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5,7-dibromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

146 of 356

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,7-dibromo-6-hydroxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-17-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[7-bromo-1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-19-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-7-bromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated

148 of 356

RN 929279-35-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-6-[(4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-37-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-39-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-bromo-1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-41-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5-bromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-43-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-55-0 CAPLUS

CN 1H-Azepine-1-carboxylic acid, hexahydro-4-[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-61-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1S)-1,3-dihydro-1,3-dioxo-2H-isindol-2-yl]cyclohexyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-66-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-45-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-47-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(6-hydroxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



Absolute stereochemistry.



RN 929279-49-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-68-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-70-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-piperidinyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-72-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3-hydroxypropyl)thio]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-74-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-(hydroxypropyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-76-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-[(methylsulfonyl)oxy]propyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-78-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-(dimethylamino)propyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

RN 929279-83-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(aminomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-00-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(1-piperazinylmethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-03-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(1-piperazinylmethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-79-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(sulfomethyl)-1H-benzimidazol-1-yl]-, 2-methyl ester, sodium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 929279-81-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[(methylamino)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-06-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(2-hydroxyethyl)thio]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-08-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[(2-hydroxyethyl)thio]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-10-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[(2-hydroxyethyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-12-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(ethenylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-14-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]difluoromethylsulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-16-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[difluoro(4-piperidylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-18-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(cyanomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-20-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(cyanomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-28-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[(trifluoromethyl)sulfonyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-19-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-22-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-34-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]-1,2-dihydroxyethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-36-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-38-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-40-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-42-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-44-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-46-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[6-[[4-[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-51-3 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-54-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-56-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-62-6 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-(acetyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-64-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(acetyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-66-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[(2R)-3-(dimethylamino)-1-oxo-2-propen-1-yl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 929280-68-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(2-chloro-3-pyridinyl)methoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 929280-70-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(2-chloro-3-pyridinyl)methoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 929280-72-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(2-chloro-3-pyridinyl)methoxy]-5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 929280-88-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-90-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-92-2 CAPLUS

RN 929280-76-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-78-4 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-84-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929280-86-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-propen-1-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-94-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2,3-dihydroxypropyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-96-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-(1,3-dioxolan-2-yl)ethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-98-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-

10522958-updated

169 of 356

oxoethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-00-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[[1-(2-chlorophenyl)ethoxy]-5-[6-(2-hydroxy-2-methoxyethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-05-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-07-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-

10522958-updated

170 of 356

(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-09-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-11-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

171 of 356

RN 929281-13-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[[1-(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-15-2 CAPLUS

CN B-Alanine, N-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-17-4 CAPLUS

CN L-Alanine, N-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated

172 of 356

RN 929281-19-6 CAPLUS

CN L-Valine, N-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-21-0 CAPLUS

CN L-Alanine, N-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-23-2 CAPLUS


CN L-Alanine, N-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-25-4 CAPLUS
 CN Carbamic acid, N-[2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-27-6 CAPLUS
 CN Carbamic acid, N-[2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]methylamino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-29-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-31-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-33-4 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[[1-(1-(2-chlorophenyl)ethoxy)-5-[6-(4-piperidinyl)-1H-benzimidazol-1-yl]-, (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-36-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-38-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[5-(2-thienyl)-1H-benzimidazol-1-yl]-3-[[1-(1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-40-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-3-[[1-(1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-42-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[1-(1-(2-chlorophenyl)ethoxy)-5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-44-7 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[1-(1-(2-chlorophenyl)ethoxy)-5-(5-phenyl-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-46-9 CAPLUS
 CN 1H-Pyrrole-1-carboxylic acid, 2-[1-[5-(methoxycarbonyl)-4-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-48-1 CAPLUS
 CN 1H-Pyrrole-1-carboxylic acid, 2-[(1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl)]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-50-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[5-(2-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-55-0 CAPLUS
 CN Imidodicarbonic acid, N-[6-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-3-pyridazinyl]]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.


RN 929281-70-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(6-chloro-5-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.





RN 929281-72-1 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[6-[(4-amino-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-73-2 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-(dimethylamino)-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-57-2 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(3,5-dimethyl-4-isoxazolyl)-1H-benzimidazol-1-yl]]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-68-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-chloro-5-[2-(trimethylsilyl)ethoxy]-1H-benzimidazol-1-yl]]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-74-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3-methoxy-3-oxopropyl)thio]methyl]-1H-benzimidazol-1-yl]]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-75-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3-methoxy-3-oxopropyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-76-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[6-[(aminosulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A




RN 929040-22-2 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-34-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-36-8 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-23-3 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-27-7 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-29-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.


RN 929040-39-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-42-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-17-0 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


189 of 356



RN 929095-18-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-19-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-20-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


190 of 356



RN 929095-21-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-22-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-23-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


191 of 356



RN 929095-40-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-45-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


192 of 356



RN 929276-39-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(6-chloro-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-41-5 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-

10522958-updated

193 of 356

3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-42-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-43-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


194 of 356



RN 929276-45-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-chloro-4-pyrimidinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-46-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyrimidinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


195 of 356



RN 929276-49-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-ethyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-50-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1R)-3-piperidinylmethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-51-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2R)-2-morpholinylmethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

10522958-updated

196 of 356


Absolute stereochemistry.



RN 929276-53-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-cyclopentyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-55-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[7-bromo-6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-58-4 CAPLUS

CN Formic acid, compd. with 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5,7-dibromo-6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide (1:1)

10522958-updated

197 of 356


(CA INDEX NAME)

CM 1

CRN 929276-57-3

CMF C25 H23 Br2 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

Ome: CH - OH

RN 929276-60-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-62-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[3-

10522958-updated

199 of 356


benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-68-6

CMF C27 H27 F3 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 929276-72-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1R)-hexahydro-1H-azepin-4-yl]oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-71-1

CMF C27 H27 F3 N4 O3 S


Absolute stereochemistry.

10522958-updated

198 of 356

(dimethylamino)propoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-64-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-66-4 CAPLUS

CN Sulfamic acid, N,N-dimethyl-, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-69-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1R)-hexahydro-1H-azepin-4-yl]oxy]-1H-

10522958-updated

200 of 356



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 929276-74-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(cis-4-aminocyclohexyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-76-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-piperidinylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-77-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-78-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-79-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-84-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[4-(piperidinyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-85-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(2-amino-2-iminoethyl)-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-87-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[4-(piperidinyl)ethenyl]-1H-benzimidazol-1-yl]]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1



RN 929276-80-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-82-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-83-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

CRN 929276-86-8
CMP C27 H27 Cl N4 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2


RN 929276-89-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[4-(piperidinyl)carbonyl]-1H-benzimidazol-1-yl]]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-88-0
CMP C26 H25 Cl N4 O3 S

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 929276-92-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(difluoro(1-methyl-4-piperidinyl)methyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-94-8 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-96-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-amino-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 929276-97-1 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-98-2 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[4-(ethylsulfonyl)-1-piperazinyl]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-99-3 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methylethyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-00-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-02-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[2-(1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 2-A

RN 929277-04-3 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(1,2-dihydro-2-oxo-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-05-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-(1-piperazinyl)-4-pyrimidinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 929277-06-5 CAPLUS

RN 929277-12-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[2-[(methylsulfonyl)ethyl]amino]ethyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-15-6 CAPLUS

CN 2-Propanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 929277-18-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(phenylsulfonyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




CN 2-Thiophenecarboxamide, 3-[(2-chloro-3-pyridinyl)methoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)



RN 929277-07-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(3-amino-2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-08-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-21-4 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-24-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-26-9 CAPLUS


CN Ethanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-27-0 CAPLUS
 CN 1-Propanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-28-1 CAPLUS
 CN Formic acid, compd. with 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl N-[3-(dimethylamino)propyl]-N-methylsulfamate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-28-1
 CMF C27 H30 F3 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


OH = CH-OH

RN 929277-32-7 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[6-[difluoro(4-piperidynylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-31-6
 CMF C27 H25 F5 N4 O4 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 929277-34-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidynyl)carbonyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-36-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[difluoro(1-methylethyl)-4-piperidynyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-40-7 CAPLUS
 CN β-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 929277-39-4
 CMF C24 H23 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 929277-43-0 CAPLUS
 CN L-Alanine, N-[[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-42-9
 CMF C26 H27 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 929277-45-2 CAPLUS
 CN L-Valine, N-[[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-44-1
 CMF C28 H31 Cl N4 O4 S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 929277-47-4 CAPLUS
CN L-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1
CRN 929277-46-3
CMF C24 H23 Cl N4 O4 S

Absolute stereochemistry.




CM 2
CRN 76-05-1



RN 929277-55-4 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-[[[(2-aminoethyl)amino]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1
CRN 929277-54-3
CMF C23 H24 Cl N5 O2 S

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 929277-61-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[(2-(dimethylamino)ethyl)methylamino]methyl]-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CMF C2 H F3 O2



RN 929277-50-9 CAPLUS
CN L-Alanine, N-[2-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1
CRN 929277-49-6
CMF C25 H25 Cl N4 O4 S

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 929277-52-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

CM 1
CRN 929277-60-1
CMF C26 H30 Cl N5 O2 S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 929277-64-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[1-(2-hydroxyethyl)-4-piperidyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-67-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[1-(2-(methylsulfonyl)ethyl)-4-piperidyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-71-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-72-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-thienyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-73-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

RN 929277-78-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-79-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-81-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-3-pyridazinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 929277-74-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5-(4-pyridinyl)-1H-benzimidazol-1-yl)- (CA INDEX NAME)



Absolute stereochemistry.



RN 929277-76-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5-phenyl-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-83-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(3,5-dimethyl-4-isoxazolyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-85-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-chloro-5-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-86-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-2-methyl-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


10522958-updated 225 of 356
benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-87-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-imidazol-5-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-88-3 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(2-amino-5-pyrimidinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




10522958-updated 227 of 356




RN 929277-96-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[4-(dimethylamino)-1-piperidinylmethyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-98-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-[(aminosulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-00-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(3-amino-4-methoxyphenyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

10522958-updated 226 of 356


RN 929277-90-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[2-(dimethylamino)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-92-9 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[2-(methylanino)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-94-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(2-methyl-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


10522958-updated 228 of 356
yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-02-4 CAPLUS
CN Benzenepropanoic acid, 3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-04-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(methylamino)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


229 of 356



RN 929278-06-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-methoxy-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-08-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-10-4 CAPLUS

10522958-updated


231 of 356



RN 929278-16-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-24-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(trans-4-aminocyclohexyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-25-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-(cis-4-aminocyclohexyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

10522958-updated

230 of 356

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(4-methyl-1-piperazinyl)-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-12-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-(4-amino-1-piperidinyl)-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-14-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(methyl(1-methyl-4-piperidinyl)amino)-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated

232 of 356


Absolute stereochemistry.



RN 929278-27-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(trans-4-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl)-12-(methylsulfonyl)ethyl]aminocyclohexyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-29-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(trans-4-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl)-12-(methylsulfonyl)ethyl]aminocyclohexyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-34-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-(trans-4-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl)-12-(methylsulfonyl)ethyl]aminocyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
AN 2007:283577 CAPLUS [Full-text](#)
DN 146:337898
TI Preparation of benzimidazolyl thiophene derivatives as PLK modulators
IN Cheung, Mui; Badiang, Jennifer Gabriel; Donaldson, Kelly Horne; Rheault, Tara Renae
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 80pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO. (NO US CASE-NOT ODP)	DATE
PI NO 2007030359	A1	20070315	NO 2006-US33616	20060828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-714303P	P	20050906	(NOT PRIOR ART)	


GI




AB The present invention provides 5-heteroaryl substituted benzimidazole thiophene derivs., pharmaceutical compns. containing the same, processes for preparing the same and their use as pharmaceutical agents. For example, 1 was provided in a multi-step synthesis starting from the reaction of Me 3-hydroxy-5-nitro-2-thiophenecarboxylate with (1S)-1-[2-(trifluoromethyl)phenyl]ethanol. The prepared title compds. were tested for inhibition of PLK-1 (polo-like kinase 1), methylene blue cell growth inhibition, cell-titer glo cell growth inhibition and pharmacokinetics.

IT 660869-61-4P 660869-62-5P 660869-69-2P
660869-93-2P 929040-02-9P, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-16-4P, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-22-2P, 5-[5-[2-[[1-methyl-4-piperidinyl]amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-25-3P, 5-[5-[2-Amino-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-27-7P, 5-[5-[1H-Pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-[[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-29-9P, 3-[[1(R)-1-[2-(chlorophenyl)ethoxy]-5-[5-[6-[[1-methyl-4-piperidinyl]amino]-3-pyridinyl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide
929040-35-8P 929040-39-1P, 3-[[1(R)-1-[2-(chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide
929040-42-6P, 3-[[1(R)-1-[2-(chlorophenyl)ethoxy]-5-[5-[1-methyl-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of benzimidazolyl thiophene deriva. as Polo-like kinases (PLK) modulators)


RN 660869-61-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[1-(2-chlorophenyl)ethoxy]-5-[5,6-dimethoxy-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 660869-62-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5,6-dimethoxy-1H-benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)



RN 660869-69-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-methoxy-5-[3-(2-oxo-1-pyrrolidinyl)propoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 660869-93-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[5-(aminocarbonyl)-4-[[2-(trifluoromethyl)phenyl]methoxy]-2-thienyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 929040-03-9 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-16-4 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1(R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 929040-22-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-((1-methyl-4-piperidinyl)amino)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-36-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-39-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-23-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-27-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-29-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-42-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]]- (CA INDEX NAME)

Absolute stereochemistry.



IT 929040-41-7P 929040-44-8P 929040-45-9P

929040-46-0P 929040-47-1P 929040-48-2P

929040-49-3P 929040-50-4P 929040-51-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolyl thiophene derivs. as Polo-like kinases (PLK) modulators)

RN 929040-43-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-44-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-

benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 929040-45-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-46-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-47-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-48-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-49-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-50-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-51-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-methyl-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 929040-05-5P, Methyl 5-[(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]thiophene-2-carboxylate

929040-11-9P 929040-14-2P 929040-18-6P, 5-[(5-Bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]thiophene-2-carboxamide
929040-21-1P, 5-[(5-(2-Fluoro-4-pyridinyl)-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]-2-thiophenecarboxamide
929040-24-4P, Methyl 5-[(5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]-2-thiophenecarboxylate
929040-25-5P, Methyl 5-[(5-[2-[(diphenylmethylidene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]-2-thiophenecarboxylate


Chemical structure: CCOC(=O)c1cc(C2=CN=CN=C2c3ccc(NC(=O)OC)cc3)nc4ccccc4C(F)(F)F
 929040-32-4F 929040-33-5F,
 5-(5-Bromo-1H-benzimidazol-1-yl)-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-2-thiophenecarboxylate 929040-28-8F, Methyl 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-2-thiophenecarboxylate 929040-32-4F 929040-33-5F,
 5-(5-Bromo-1H-benzimidazol-1-yl)-3-((1R)-1-(2-(chlorophenyl)ethyl)oxy)thiophene-2-carboxamide 929040-34-6F,
 3-((1R)-1-(2-Chlorophenyl)ethyl)oxy]-5-[5-(6-fluoropyridin-3-yl)-1H-benzimidazol-1-yl]thiophene-2-carboxamide 929040-37-5F
 929040-38-6P, 1,1-Dimethylethyl 4-[5-[1-[5-(aminocarbonyl)-4-((1R)-1-(2-chlorophenyl)ethyl)oxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-1-piperazinecarboxylate 929040-40-4F
 929040-41-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazolyl thiophene deriva. as Polo-like kinases (PLK) modulators)

RN 929040-09-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-11-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-14-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-18-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-21-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-24-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-25-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[2-[(diphenylmethylene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-26-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-28-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-32-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-33-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-34-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-41-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-(3-(4-ethyl-1-piperazinyl)propyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-37-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-38-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:282094 CAPLUS Full-text

DN 146:337890

TI Preparation of thiophenyl benzimidazole derivatives for treatment of conditions mediated by polo-like kinases

IN Cheung, Mui; Emmotte, Kyle Allen; Salovich, James Michael

PA Smithkline Beecham Corp., USA

SO PCT Int. Appl., 107pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007030361	A2	20070315	WO 2006-US33683	20060828
WO 2007030361	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, CA				
US 2007270437	A1	20071122	US 2006-467577	20060828

PRAI US 2005-714337P


US 2006-786244P

GI

(CHECKED DOC - NOT GSP FOR INSTANT ELECTED)

20050906 (NOT PRIOR ART)

20060327



1

AB Eight thiophenyl benzimidazole derivs. and pharmaceutically acceptable salts and solvates thereof were prepared for the treatment of conditions mediated by polo-like kinases (PLK). For example, N-methylpiperazine was treated with Me 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[[{(1R)-1-[2-(trifluoromethyl)phenyl]ethyl]oxy]thiophene-2-carboxylate (preparation given) at 60 °C for 18 h in dioxane to give an intermediate which was further reacted with ammonia in MeOH at 80 °C for 40 h in a sealed flask to give 1 as a final product. 1 showed superior enzyme and cell potency in PLK1 enzyme assay and methylene blue cell proliferation assay in multiple cell lines. I also had superior protein binding in human serum by equilibrium dialysis assay. On the other hand, 1 showed good solubility in 0.05 M pH 7.4 phosphate buffer.

IT 929095-16-9P 929095-17-0F 929095-18-1P
929095-19-2P 929095-20-5P 929095-21-6P
929095-22-7F 929095-23-8F 929095-24-1P
929095-25-1P 929095-26-1P 929095-27-4P
929095-28-7P 929095-29-8F 929095-30-6P
929095-31-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)

RN 929095-16-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-17-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-18-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-19-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-20-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-21-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-22-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-23-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-26-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-27-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-28-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


257 of 356



RN 929095-29-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1S)-1-(2-chlorophenyl)ethoxy]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-30-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-31-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


258 of 356



RN 929095-32-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-33-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 660869-56-7 660869-61-4 660869-62-5

660869-71-6 660869-79-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)

10522958-updated

259 of 356


RN 660869-56-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)-1H-benzimidazol-1-yl]-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 660869-61-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-(2-chlorophenyl)ethoxy]-5-[5,6-dimethoxy-1H-benzimidazol-1-yl]- (CA INDEX NAME)



RN 660869-62-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5,6-dimethoxy-1H-benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)




RN 660869-71-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-methoxy-6-[2-(4-methyl-1-piperazinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)


10522958-updated

260 of 356



RN 660869-79-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-piperidinyl)methoxy]-1H-benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)



IT 440876-07-5P 929095-36-5P 929095-29-6P

929095-40-3P 929095-41-3P 929095-42-1P

929095-43-2P 929095-44-3P 929095-45-4P

929095-46-5P 929095-47-6P 929095-48-7P

929095-49-8P 929095-50-1P 929095-51-2P

929095-52-3P 929095-53-4P 929095-54-5P

929095-55-6P 929095-56-7P 929095-57-8P

929095-58-9P 929095-59-0P 929095-60-1P

929095-61-2P 929095-62-3P 929095-63-4P

929095-64-5P 929095-65-6P 929095-66-7P

929095-67-8P 929095-68-9P 929095-69-0P


929095-70-1P 929095-71-2P 929095-72-3P

929095-73-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)

RN 660870-07-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-bromo-1H-benzimidazol-1-yl]-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 929095-38-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-((2,2-dimethyl-1-oxopropoxy)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-39-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-40-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-45-4 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929095-46-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-bromo-1H-benzimidazol-1-yl]-3-[(1,1-dimethyl-2-ethoxy)dimethylsilyloxy]-, methyl ester (CA INDEX NAME)



RN 929095-41-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-42-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-((methylthio)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-43-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-((methylsulfonyl)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-47-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-48-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-ethenyl-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-49-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(1,2-dihydroxyethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


265 of 356



RN 929095-50-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(2-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-51-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-54-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(methoxymethoxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


267 of 356



RN 929095-62-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-63-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


266 of 356



RN 929095-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(2-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-5-[6-[[[(trifluoromethyl)sulfonyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-59-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(dimethoxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958-updated


268 of 356



RN 929095-66-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-67-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-hydroxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-71-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-74-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-75-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-76-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

RN 929095-79-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



X L6 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2007:181791 CAPLUS [Full-text](#)

DN 146:414432

TI In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

AU Lansing, Timothy J.; McConnell, Randy T.; Duckett, Derek R.; Spehar, Glenn M.; Knick, Victoria B.; Hassler, Daniel F.; Moro, Nobuhiro; Furuta, Masaaki; Emmitte, Kyle A.; Gilmer, Tona M.; Mook, Robert A., Jr.; Cheung, Mui

CS Oncology Biology, GlaxoSmithKline, Research Triangle Park, NC, USA
SO [Molecular Cancer Therapeutics](#) (2007), 6(2), 450-459 [NOT PRIOR ART/ODP]

CODEN: MCTOCF; ISSN: 1535-7163

PB American Association for Cancer Research


DT Journal

LA English

AB Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have shown that PLK1 expression is elevated in a variety of tumors, and high expression often correlates with poor prognosis. Using a variety of methods, including small-mol. inhibition of PLK1 function and/or activity, apoptosis in cancer cell lines, cell cycle arrest in normal cell lines, and antitumor activity in vivo have been observed. In the present study, the authors have examined the in vitro biol. activity of a novel and selective thiophene benzimidazole ATP-competitive inhibitor of PLK1 and PLK3 (5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide, called compound 1). Compound 1 has low nanomolar activity against the PLK1 and PLK3 enzymes and potentially inhibits the proliferation of a wide variety of tumor cell lines. In the lung adenocarcinoma cell line NCI-H460, compound 1 induces a transient G2-M arrest, mitotic spindle defects, and a multinucleate phenotype resulting in apoptosis, whereas normal human diploid fibroblasts arrest in G2-M and show little apoptosis. The authors also describe a cellular mechanistic assay that was developed to identify potent intracellular inhibitors of PLK1. In addition to its potential as a therapeutic agent for treating cancer, compound 1 is also a useful tool mol. for further investigation of the biol. functions of PLK1 and PLK3.

(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-77-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-78-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 660868-91-7

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro biol. activity of a small-mol. inhibitor of polo-like kinase 1)

RN 660868-91-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:1190032 CAPLUS [Full-text](#)

DN 146:54723

TI 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK- α kinase

AU Bamborough, Paul; Christopher, John A.; Cutler, Geoffrey J.; Dickson, Marion C.; Mellor, Geoffrey W.; Morey, James V.; Patel, Champa B.; Shewchuk, Lisa M.

CS Medicines Research Centre, GlaxoSmithKline R & D, Hertfordshire, SG1 2NY, UK

SO [Bioorganic & Medicinal Chemistry Letters](#) (2006), 16(24), 6236-6240

CODEN: BMCLES; ISSN: 0960-894X [NOT PRIOR ART/NOT ODP]


PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 146:54723

GI




AB The identification and hit-to-lead exploration of a novel, potent and selective series of substituted benzimidazole-thiophene carbonitrile inhibitors of IKK- ϵ kinase is described. Compound 12e (I) was identified with an IKK- ϵ enzyme potency of pIC₅₀ 7.4, and has a highly encouraging wider selectivity profile, including selectivity within the IKK kinase family.

IT 916985-24-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK- ϵ kinase)

RN 916985-24-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy- (CA INDEX NAME)



IT 960869-82-9P 862812-86-0P 862812-89-3P

862812-94-0P 862812-98-4P 862813-04-5P

916985-24-5P 862813-17-0P 916985-36-9P


916985-39-2P 916985-41-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK- ϵ kinase)


RN 960869-82-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 862812-86-0 CAPLUS

CN 2-Thiophenecarbonitrile, 3-[(1R)-1-[(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



RN 862813-04-5 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RN 862813-12-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862813-17-0 CAPLUS


CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862812-89-3 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862812-94-0 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 862812-98-4 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(methylsulfonyl)phenyl]methoxy]- (CA INDEX NAME)




RN 916985-36-9 CAPLUS

CN 2-Thiophenecarbonitrile, 3-(cyclopropylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 916985-39-2 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 916985-41-6 CAPLUS


CN Benzamide, 4-[[[2-cyano-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-thienyl]oxy]methyl]- (CA INDEX NAME)




IT 660868-19-3 660868-19-3 660868-19-3 660868-19-3
 660868-19-3 660868-19-3 660868-19-3 660868-19-3
 91-985-23-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazolyl) alkoxy thiophenecarbonitriles as inhibitors of IKK- κ kinase
 RN 660868-19-3 CAPLUS
 CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-[(4-methylphenyl)methoxy]- (CA INDEX NAME)




RN 660870-60-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862813-19-2 CAPLUS



RN 916985-22-3 CAPLUS
 CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-methylsulfonyl)phenyl]methoxy]- (CA INDEX NAME)




IT 916985-25-6 916985-25-6 916985-25-6 916985-25-6
 916985-25-6 916985-25-6 916985-25-6 916985-25-6
 91-985-23-2
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (benzimidazolyl) alkoxy thiophenecarbonitriles as inhibitors of IKK- κ kinase
 RN 916985-25-6 CAPLUS
 CN 2-Thiophenecarbonitrile, 3-hydroxy-5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 916985-26-7 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 862813-28-3 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-38-5 CAPLUS
 CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 916985-21-2 CAPLUS
 CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-methylsulfonyl)phenyl]methoxy]- (CA INDEX NAME)

CN 2-Thiophenecarbonitrile, 3-hydroxy-5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 916985-27-8 CAPLUS
 CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-hydroxy- (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2006:1190017 CAPLUS Full-text
 DN 146:74597
 TI Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists
 AU Bell, Ian M.; Bednar, Rodney A.; Fay, John F.; Gallicchio, Steven N.; Hochman, Jerome H.; McMasters, Daniel R.; Miller-Stein, Cynthia; Moore, Eric L.; Mosser, Scott D.; Pudvah, Nicole T.; Quigley, Amy G.; Salvatore, Christopher A.; Stump, Craig A.; Theberge, Cory R.; Wong, Bradley K.; Zartman, C. Blair; Zhang, Xu-Fang; Kane, Stefanie A.; Graham, Samuel L.; Vacca, Joseph P.; Williams, Theresa M.
 CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(24), 6165-6169 [NOT PRIOR ART/ODP]
 CODEN: BMCL68; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 146:74597
 GI



AB A rapid analog approach to identification of spirohydanotin-based CGRP antagonists provided novel, low mol. weight leads. Modification of these leads afforded a series of nanomolar benzimidazolinone-based CGRP receptor antagonists. The oral bioavailability of these antagonists was inversely correlated with polar surface area, suggesting that membrane permeability was a key limitation to absorption. Optimization provided compound 12 (I), a potent CGRP receptor antagonist ($K_i = 21$ nM) with good oral bioavailability in three species.


IT 916919-57-5

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (orally bioavailable spirohydanotin CGRP receptor antagonists)

RH 916919-57-5 CAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(2'R)-1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-2,3-dihydro-2-oxo-3-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:1172142 CAPLUS [Full-text](#)

DN 146:55726

TI Bayesian-regularized genetic neural networks applied to the modeling of

SO *Journal of Organic Chemistry* (2006), 71(21), 8324-8327

CODEN: JOCEAH; ISSN: 0022-3263 [\[NOT PRIOR ART/ODP\]](#)

PB American Chemical Society

DT Journal

LA English

OS CASREACT 145:505375


AB Solvent-free copper-catalyzed N-arylations of imidazoles with aryl and heteroaryl halides have been demonstrated. In the presence of CuBr, 2-aminopyrimidine-4,6-diol, and TBAF (n-Bu4NF), a variety of imidazoles underwent the N-arylation reaction with aryl and heteroaryl halides smoothly in moderate to excellent yields. Noteworthy is that the reaction was conducted under solvent-free conditions.

IT 884068-82-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of N-arylbenzimidazoles via copper-aminopyrimidinol-catalyzed N-arylation with imidazoles or benzimidazoles with aryl halides under solvent-free conditions)

RN 884068-82-0 CAPLUS

CN 1H-Benzimidazole, 1-(2-thienyl)- (CA INDEX NAME)



RE.CNT 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:398159 CAPLUS [Full-text](#)

DN 145:83268

TI CuI catalyzed C-N bond forming reactions between aryl/heteroaryl bromides and imidazoles in [Bmim]BF₄

AU Lv, Xin; Wang, Zhining; Bao, Weiliang

CS Zhejiang University, Department of Chemistry, Zhejiang, 310028, Peop. Rep. China

SO *Tetrahedron* (2006), 62(20), 4756-4761

CODEN: TETRAH; ISSN: 0040-4020 [\[NOT PRIOR ART/ODP\]](#)

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 145:83268

AB By using CuI as the catalyst and L-Proline as the ligand, the Ullmann-type coupling reactions of aryl/heteroaryl bromides and imidazoles in [Bmim]BF₄ at 105-115 °C gave the corresponding N-arylbenzimidazoles/N-heteroarylbenzimidazoles in good yields. The system offers a convenient, recyclable, and environmentally benign method for these coupling reactions.

IT 312959-35-6P 884068-82-0P 892423-38-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(copper catalyzed Ullmann-type coupling reaction of aryl/heteroaryl bromides and imidazoles in ionic liq.)

RN 312959-35-6 CAPLUS

CN 1H-Benzimidazole, 1-(3-thienyl)- (CA INDEX NAME)

non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor

AU Fernandez, Michael; Caballero, Julio

CS Molecular Modeling Group, Center for Biotechnological Studies, University of Matanzas, Matanzas, 44740, Cuba

SO *Journal of Molecular Graphics & Modelling* (2006), 25(4), 410-422

CODEN: JMGWFI; ISSN: 1093-3263 [\[NOT PRIOR ART/ODP\]](#)

PB Elsevier Inc.

DT Journal

LA English

AB Bayesian-regularized genetic neural networks (BRGNNs) were used to model the binding affinity (IC₅₀) for 128 non-peptide antagonists for the human LH-releasing hormone (LHRH) receptor using 2D spatial autocorrelation vectors. As a preliminary step, a linear dependence was established by multiple linear regression (MLR) approach, selecting the relevant descriptors by genetic algorithm (GA) feature selection. The linear model showed to fit the training set ($N = 102$) with $R^2 = 0.746$, meanwhile BRGNN exhibited a higher value of $R^2 = 0.871$. Beyond the improvement of training set fitting, the BRGNN model overcame the linear one by being able to describe 85% of test set ($N = 26$) variance in comparison with 73% the MLR model. The authors' non-linear QSAR model illustrates the importance of an adequate distribution of atomic properties represented in topol. frames and reveals the electronegativities, masses and polarizabilities as the most influencing atomic properties in the structures of the heterocycles under anal. for having an appropriate LHRH antagonistic activity. Furthermore, the ability of the non-linear selected variables for differentiating the data was evidenced when total data set was well distributed in a Kohonen self-organizing map (SOM).


IT 917017-69-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(Bayesian-regularized genetic neural networks applied to modeling binding affinity for non-peptide antagonists for human LH-RH receptor using 2D spatial autocorrelation vectors)

RN 917017-69-7 CAPLUS

CN 1H-Benzimidazole-5-sulfonamide, 2-ethoxy-N-[(4-fluorophenyl)methyl]-1-(3-thienyl)- (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS ON STN


AN 2006:971442 CAPLUS [Full-text](#)

DN 145:505375

TI 2-Aminopyrimidine-4,6-diol as an efficient ligand for solvent-free copper-catalyzed N-arylations of imidazoles with aryl and heteroaryl halides


AU Xie, Ye-Xiang; Pi, Shao-Feng; Wang, Jian; Yin, Du-Lin; Li, Jin-Heng

CS Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research (Ministry of Education), College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha, 410081, Peop. Rep. China




RN 884068-82-0 CAPLUS

CN 1H-Benzimidazole, 1-(2-thienyl)- (CA INDEX NAME)



RN 892483-38-4 CAPLUS

CN 1H-Benzimidazole, 1-(5-methyl-2-thienyl)- (CA INDEX NAME)



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2005:823697 CAPLUS [Full-text](#)

DN 143:329853

TI Preparation of benzimidazolyl substituted thiophene derivatives with activity against IKK3

IN Bamborough, Paul; Morey, James Vaughan

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005075465	A1	20050818	WO 2005-EP1432	20050207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
EP 1720864	A1	20061115	EP 2005-707356	20050207


R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV
 JP 2007522142 T 20070809 JP 2006-551827 20050207
 US 2007149519 A1 20070628 US 2006-597828 20060909
 (NOT ODP AGAINST ELECTROD CPD)
 PRAI GB 2004-2809 A 20040209
 WO 2005-EP1432 W 20050207 - NOT PRIOR ART
 OS CASREACT 143:229853; MARPAT 143:229853
 GI



AB The title compds. I [n = 0-4; R1 = H, halo, XaYbZ (wherein X = O, CONH, a = 0-1; Y = alkylene; b = 0-1; Z = OR, alkyl, haloalkyl, etc.); R2 = (X1)(Y1)dZ1 (X1 = alkylene; c = 0-1; Y1 = O; d = 0-1; Z1 = H, aryl, heteroaryl, etc.)] which are potentially useful in the treatment of diseases associated with inappropriate I-kappa-B kinase-3 (IKK3) (also known as I-kappa-B kinase epsilon (IKKε) or inducible I-kappa-B kinase (IKKi)) activity, were prepared. Thus, treating a solution of 5-[5,6-bis(methoxy)-1H-benzimidazol-1-yl]-3-[(4-(hydroxymethyl)phenyl)methoxy]-2-thiophenecarboxamide and pyridine in CH2Cl2 with trifluoroacetic anhydride at -10°C afforded II which showed pIC50 of >6.0 when tested in IKK3 assay. The pharmaceutical composition comprising the compound I is disclosed.


IT 862812-84-1P 862812-85-1P 862812-86-1P 862812-87-1P 862812-88-1P 862812-89-1P 862812-90-1P 862812-91-1P 862812-92-1P 862812-93-1P 862812-94-1P 862812-95-1P 862812-96-1P 862812-97-1P 862812-98-1P 862812-99-1P 862813-00-1P 862813-01-1P 862813-02-1P 862813-03-1P 862813-04-1P 862813-05-1P 862813-06-1P 862813-07-1P 862813-08-1P 862813-09-1P 862813-10-1P 862813-11-1P 862813-12-1P 862813-13-1P 862813-14-1P 862813-15-1P 862813-16-1P 862813-17-1P 862813-18-1P 862813-19-1P 862813-20-1P 862813-21-1P 862813-22-1P 862813-23-1P 862813-24-1P 862813-25-1P
 RL, PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzimidazolyl substituted thiophene derivs. with activity against IKK3)
 RN 862812-84-2 CAPLUS
 CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-[(2-

methylphenyl)methoxy]- (CA INDEX NAME)




RN 862812-82-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)



RN 862812-84-8 CAPLUS


CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-(hydroxymethyl)phenyl)methoxy]- (CA INDEX NAME)



RN 862812-86-0 CAPLUS


CN 2-Thiophenecarbonitrile, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862812-89-3 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862812-92-8 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1-methyl-1H-benzotriazol-6-yl)methoxy]- (CA INDEX NAME)




RN 862812-94-0 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 862812-96-2 CAPLUS

CN 2-Thiophenecarbonitrile, 3-[(2,5-difluorophenyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 862812-98-4 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(methylsulfonyl)phenyl)methoxy]- (CA INDEX NAME)




RN 862813-00-1 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5-chloro-1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862813-02-3 CAPLUS


CN 2-Thiophenecarbonitrile, 3-[(2,6-difluorophenyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 862813-04-5 CAPLUS
CN 2-Thiophenecarbonitrile, 5-[(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 862813-06-7 CAPLUS
CN 2-Thiophenecarbonitrile, 3-[(3-bromo-4-pyridinyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 862813-08-9 CAPLUS
CN 2-Thiophenecarbonitrile, 3-(cyclohexylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 862813-15-8 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethoxy)phenyl]methoxy]- (CA INDEX NAME)




RN 862813-16-9 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-methoxyphenyl]methoxy]- (CA INDEX NAME)



RN 862813-17-0 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 862813-10-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[5-cyano-4-[[2-(trifluoromethyl)phenyl]methoxy]-2-thienyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 862813-12-5 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.




RN 862813-14-7 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-phenylethoxy)- (CA INDEX NAME)




RN 862813-18-1 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 862813-19-2 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 862813-20-5 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 862813-21-6 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenoxyethoxy)- (CA INDEX NAME)




RN 862813-22-7 CAPLUS
CN 2-Thiophenecarbonitrile, 3-[(1S)-1-(2-chlorophenyl)butoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862813-23-8 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(3-thienylmethoxy)- (CA INDEX NAME)




RN 862813-24-9 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-thienylmethoxy)- (CA INDEX NAME)




RN 862813-25-0 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-methylpropoxy]- (CA INDEX NAME)

Absolute stereochemistry.




IT 660869-28-7 660869-35-0 660869-51-7
660869-17-0 660869-34-1 660869-42-1
660869-46-5 660869-47-6 660869-45-7
660869-49-8 660869-55-6 660869-26-1
660869-28-3 660869-23-4 660869-20-7
660869-31-5 660869-32-9 660869-33-0
660869-34-1 660869-35-2 660869-36-3
660869-37-4 660869-38-5 660869-39-6
660869-40-9 660869-41-0 660869-42-1


660869-34-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazolyl substituted thiophene derivs. with activity against IKK3)
RN 660869-28-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-[(2-methylphenyl)methoxy]- (CA INDEX NAME)




RN 660869-36-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 660869-91-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 660869-17-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-(5-chloro-1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 660869-34-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(methylsulfonyl)phenyl)methoxy]- (CA INDEX NAME)



RN 660869-42-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethoxy)phenyl)methoxy]- (CA INDEX NAME)




RN 660869-46-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-(cyclohexylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 660869-47-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2H-pyran-2-yl)methoxy]]- (CA INDEX NAME)




RN 660869-48-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(4-morpholinyl)ethoxy]]- (CA INDEX NAME)




RN 660869-49-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenylethoxy)]- (CA INDEX NAME)




RN 660869-55-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(3-bromo-4-pyridinyl)methoxy]-5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)]- (CA INDEX NAME)



RN 862813-26-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[4-(hydroxymethyl)phenyl)methoxy]]- (CA INDEX NAME)



RN 862813-28-3 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-29-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1-methyl-1H-benzotriazol-6-yl)methoxy]]- (CA INDEX NAME)




RN 862813-30-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[(6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)phenyl)methoxy]]- (CA INDEX NAME)




RN 862813-31-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(2,5-difluorophenyl)methoxy]-5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)]- (CA INDEX NAME)




RN 862813-32-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(2,6-difluorophenyl)methoxy]-5-[(5,6-dimethoxy-1H-benzimidazol-1-yl)]- (CA INDEX NAME)




RN 862813-33-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl)methoxy]]- (CA INDEX NAME)



RN 862813-34-1 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-[5-(aminocarbonyl)-4-[[2-(trifluoromethyl)phenyl)methoxy]-2-thienyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 862813-35-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-36-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-methoxyphenyl)methoxy))- (CA INDEX NAME)




RN 862813-37-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-oxo-1-pyrrolidinyl)ethoxy))- (CA INDEX NAME)




RN 862813-41-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((3-thienyl)methoxy))- (CA INDEX NAME)



RN 862813-42-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-thienyl)methoxy))- (CA INDEX NAME)



RN 862813-43-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((1R)-1-methylpropoxy))- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-38-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-phenoxyethoxy))- (CA INDEX NAME)



RN 862813-39-6 CAPLUS


CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-phenoxyethoxy))- (CA INDEX NAME)



RN 862813-40-9 CAPLUS



CN 2-Thiophenecarboxamide, 3-(((1S)-1-(2-chlorophenyl)butoxy))-5-((5,6-dimethoxy-1H-benzimidazol-1-yl))- (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2005:371254 CAPLUS [Full-text](#)
 DN 142:430276
 TI Process for preparing thienylbenzimidazoles from benzimidazoles and 2-chloro-3-oxo-2,3-dihydrothiophene-2-carboxylates.
 IN Cheung, Mui; Emmitte, Kyle Allen
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005037827	A1	20050428	WO 2004-US33585	20041012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TW, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, CH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685128	A1	20060802	EP 2004-794836	20041012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR JP 2007509070 T 20070412 JP 2006-535584 20041012 US 2007060576 A1 20070315 US 2006-575210 20060410 (NOT ODP - PROCESS MAKING)				
PRAI US 2003-511991P	P	20031016	NOT PRIOR ART	
WO 2004-US33585	M	20041012		
OS CASREACT 142:430276; MARPAT 142:430276				
OI				




AB Title compds. [I; R1 = H, alkyl, alkenyl, alkynyl, COR7, CO2R7, cyano, (substituted) heterocyclyl, etc.; Q1 = (R2)a(Y1)b(R2)cR3; a, b, c, aa, bb, cc = 0, 1; 21 of, a, b = 1; n = 0-4; Q4 = (R2)aa(Y2)bb(R2)ccR4; Y1, Y2 = O, CO, CO2, OSO2, CONR7, etc.; R2 = alkylene, alkenylene, alkynylene; R3, R4 = H, halo, alkyl, alkenyl, alkynyl, COR7, CO2R7, NO2, cyano, R3, etc.; R5 = H, halo, alkyl, cycloalkyl, OR7, NHSO2R7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, were prepared by treatment of the corresponding N-unsubstituted benzimidazoles with 2-chloro-3-oxo-2,3-dihydrothiophene-2-carboxylates (II; R10 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, protecting group) in the presence of base. Thus, benzimidazole in CHCl3 was treated with Me 2-chloro-3-oxo-2,3-dihydro-2-thiophenecarboxylate and NaHCO3 followed by stirring for 16 h to give Me 5-(1H-benzimidazol-1-yl)-3-hydroxy-2-thiophenecarboxylate.

IT 113387-25-2P 660870-4P 660870-50-3P
 660870-12-3P
 RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (process for preparing thienylbenzimidazoles from benzimidazoles and chlorooxodihydrothiophenecarboxylates)

RN 113387-85-2 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)





RN 660870-49-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[6-[(1,1-dimethylethoxy)carbonyl]amino]-1H-benzimidazol-1-yl]-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 660870-50-8 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[5-[(1,1-dimethylethoxy)carbonyl]amino]-1H-

EP 1608627 A2 20051228 EP 2004-719222 20040310
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 JP 2006520383 T 20060907 JP 2006-507033 20040310
 US 2006211712 A1 20060921 US 2005-549338 20050913
 US 7202251 B2 20070410
 PRAI US 2003-455609P P 20030314
 US 2003-486642P P 20030711
 WO 2004-057289 A 20040310
 OS CASREACT 141:314324; MARPAT 141:314324
 GI




AB The title compds. [I; B = (un)substituted bicycloheterocycle; A1, A2 = a bond, (un)substituted CH2; R4 = H, alkyl, fluoroalkyl, cycloalkyl, etc.; R51, R52, R53 = H, alkyl, alkoxy, etc.; R6 = H, alkyl, cycloalkyl, etc.; m, n = 1-2] that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache, were prepared. E.g., a multi-step synthesis of II, starting from 6-bromo-2-tetralone, was given. The exemplified compds. I had activity as antagonists of the CGRP receptor, generally with a Ki or IC50 value of <50nM. The invention is also directed to pharmaceutical compds. comprising the compds. I and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.


IT 767304-28-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists)

RN 767304-28-9 CAPLUS
 CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-[2H]inden]-5'-yl)-2,3-dihydro-2-oxo-3-(2-thienyl)- (CA INDEX NAME)

benzimidazol-1-yl]-3-hydroxy-, methyl ester (CA INDEX NAME)




RN 850850-12-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(5,6-dihydroxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


X L6 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2004:799443 CAPLUS Full-text
 DN 141:314324
 TI Preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists
 IN Bell, Ian M.; Gallicchio, Steven N.; Theberge, Cory R.; Zhang, Xu-Fang; Stump, Craig; Zartman, C. Blair
 PA Merck & Co. Inc., USA
 SO PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CVT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004082605	A2	20040930	WO 2004-US7289	20040310
WO 2004082605	A3	20041118		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG				
AU 2004222383	A1	20040930	AU 2004-222383	20040310
CA 2519475	A1	20040930	CA 2004-2519475	20040310




IT 767304-90-2P 767105-35-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists)

RN 767304-90-3 CAPLUS
 CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-2-oxo-3-(2-thienyl)- (CA INDEX NAME)



RN 767305-38-4 CAPLUS
 CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-2-oxo-3-(tetrahydro-1,1-dioxido-3-thienyl)- (CA INDEX NAME)



L6 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - MAYBE NEXT NE - CHECK!!
 AN 2004:2863 CAPLUS Full-text
 DN 140:77149
 TI Preparation of benzimidazoles as estrogen agonists/antagonists
 IN Chesworth, Richard; Gagnas, Laura Dianne
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 111 pp.
 CODEN: PIXXD2
 DT Patent
 LA English


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
P1 WO 2004/000817	A2	20031231	WO 2003-1B2670	20030612
WO 2004/000817	A3	20040521		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BP, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MN, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 2004/002524	A1	20040101	US 2003-460565	20030611
CA 2447266	A1	20031231	CA 2003-2487266	20030612
AU 2003/38597	A1	20040106	AU 2003-238597	20030612
BR 2003012069	A	20030329	BR 2003-12069	20030612
EP 1517897	A2	20030330	EP 2003-732945	20030612
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005534675	T	20051117	JP 2004-515164	20050612
MX 2004/PA11123	A	20050214	MX 2004-PA11123	20041109
PRAI US 2002/391337P	P	20020624		
WO 2003/1B2670	W	20030612		
OS MARPAT 140:77149				
G1				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I (wherein R1, R2 = independently (un)substituted alkyl, Ph, heteroaryl, cycloalkyl, cycloalkenyl, (un)substituted 4-hydroxyphenyl; R3, R4, R5, R6 = independently H, OH, alkyl, alkoxy, halo; with the proviso that at least one of R1 or R2 must be (un)substituted 4-hydroxyphenyl; their prodrugs, pharmaceutical acceptable salts, or stereoisomeric mixture of I, prodrug or salt) were prepared as estrogen agonists and/or antagonists for treating estrogen receptor-mediated diseases (no data). For example, II was prepared in 5 steps via cyclocondensation of III (preparation given) in AcOH at 80° overnight to the corresponding methoxyphenylbenzimidazole followed by deprotection. Selected I are selective for the ER β receptor (no data).

IT 639523-96-9 4-[1-(3-thienyl)-1H-benzimidazol-2-yl]phenol
639523-96-10 4-[1-(Thiophen-2-yl)-1H-benzimidazol-2-yl]phenol
R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(estrogen agonist/antagonist; preparation of benzimidazoles as estrogen agonists/antagonists)

RN 639523-96-9 CAPLUS
CN Phenol, 4-[1-(3-thienyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 639523-98-1 CAPLUS
CN Phenol, 4-[1-(2-thienyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




IT 639523-97-0 2-(4-Methoxyphenyl)-1-thiophen-3-yl-1H-benzimidazole
639523-96-11 2-(4-Methoxyphenyl)-1-thiophen-2-yl-1H-benzimidazole
R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazoles as estrogen agonists/antagonists)

RN 639523-97-0 CAPLUS
CN 1H-Benzimidazole, 2-(4-methoxyphenyl)-1-(3-thienyl)- (CA INDEX NAME)



RN 639523-99-2 CAPLUS
CN 1H-Benzimidazole, 2-(4-methoxyphenyl)-1-(2-thienyl)- (CA INDEX NAME)



X L6 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
(NOT 101 B/C NO MOTIVATION TO MODIFY)

AN 2003:195536 CAPLUS Full-text
DN 139:52841

T1 N-azolylmethyl ketones as building blocks in heterocyclic synthesis: Synthesis of new polyfunctionally substituted azolylylazophenols, azolylylpyridones and azolylylthiophenes

AU Al-Saleh, Balkis; Abdelkhalik, Mervat Mohammed; El-Asasery, Morsy Ahmed; Elmagdi, Mohammed Hilmy

CS Department of Chemistry, Faculty of Science, University of Kuwait, Safat, 13060, Kuwait

SO Journal of Heterocyclic Chemistry (2003), 40(1), 171-175
CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation

DT Journal

LA English

OS CASREACT 139:52841


G1

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. reacted with 2-arylhydrazonopropanals to yield polyfunctionally substituted azolylylazophenols, e.g. I and II. The reaction of 1-(1H-benzimidazol-1-yl)-2-propanone and 1-(1H-1,2,4-triazol-1-yl)-2-propanone with phenylisothiocyanate in the presence of α -haloketones afforded the azolylylthiophenes III (R = Me, Ph) and IV (R = Me, Ph). The reaction of V with α -haloketone afforded 5-benzotriazol-1-yl-6-methyl-2-(2-oxopropyl)bulfinylpyridine VI that was utilized as building blocks for the synthesis of condensed pyridines. Compound VI was condensed with DMF dimethylacetate to yield thieno[2,3-b]pyridin-3-yl-N,N-dimethylformamide derivative VII. This was further cyclized with sodium hydride to 1H-thieno[2,3-b:4,5-b']dipyridin-4-one derivative VIII.


IT 544692-67-3 CAPLUS
R1: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of new polyfunctionally substituted azolylylazophenols, azolylylpyridones and azolylylthiophenes using N-azolylmethyl ketones as building blocks)

RN 544692-67-3 CAPLUS
CN Ethanone, 1-[4-(1H-benzimidazol-1-yl)-3-methyl-5-(phenylamino)-2-thienyl]- (CA INDEX NAME)



RN 544692-81-1 CAPLUS
CN Methanone, [4-(1H-benzimidazol-1-yl)-3-methyl-5-(phenylamino)-2-

thienyl]phenyl- (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - MAYBE NEXT NE - CHECK!!

AN 2002:849613 CAPLUS Full-text
DN 137:353066

T1 Preparation of nitrogenous fused-ring compound having pyrazolyl group as substituents as inhibitors of activation of signal transduction and activation of transcription (STAT6) protein

IN Yoshida, Ichiro; Yoneda, Naoki; Onashi, Yoshiaki; Suzuki, Shuichi; Miyamoto, Mitsuaki; Miyazaki, Futoshi; Seshimo, Hidenori; Kanata, Junichi; Takase, Yasutaka; Shirato, Manabu; Shimokubo, Daiya; Sakuma, Yoshinori; Yokohama, Hiromitsu

PA Eisai Co., Ltd., Japan


SO PCT Int. Appl., 1006 pp.
CODEN: PIXXD2

DT Patent

LA Japanese


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
P1 WO 2002089107	A1	20021107	WO 2002-JP4156	20020425
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MM, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
AU 2002253596	A1	20021111	AU 2002-253596	20020425
EP 1382603	A1	20040121	EP 2002-722791	20020425
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 7074901	B1	20060711	US 2003-475585	20031023
PRAI JP 2001-129959	A	20010426		
WO 2002-JP4156	W	20020425		
OS MARPAT 137:353066				
G1				




AB The 4-(N-containing fused aromatic heterocyclyl)pyrazoles (I) or salts thereof, or hydrates of either [X = a nitrogenous fused aromatic heterocyclic group, e.g., imidazo[1,2-a]pyridine, having (R4)n as a substituent; wherein n = an integer of 0-3; R4 = H, halo, cyano, OH, NH2, C1-6 alkyl, halo-C1-6 alkyl, C2-6 alkenyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, C1-6 alkylsulfinyl, N-mono, or N,N-di(C1-6 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfonyl, CONH2, etc.; Y = C3-8 cycloalkyl, C4-8 cycloalkenyl, 5- to 14-membered nonarom. or aromatic heterocyclyl, C6-14 aromatic hydrocarbyl, benzene- or 5- or 6-membered aromatic heterocycle-fused 5- to 7-membered nonarom. ring group; Z = H, NH2, halo, HO, NO2, cyano, N3, CHO, HOXN, SO2NH2, guanidino, oxo, C2-6 alkenyl, C1-6 alkoxy, etc.; R1 = H, halo, HO, NO2, cyano, halo-C1-6 alkyl, hydroxy- or cyano-C1-6 alkyl, C2-6 alkenyl, etc.; R2 = H, pyrazolyl; R3 = H, halo, cyano, NH2, C1-4 alkyl, halo-C1-4 alkyl] are prepared. These compds. are inhibitors of STAT6 protein activation and IL-4 and/or IL-13 signal transduction and are useful for prevention and/or treatment of diseases on which the inhibition of STAT6 activation and/or IL-4 and/or IL-13 signal transduction is effective. The diseases include allergy, allergic rhinitis, bronchial asthma, atopic dermatitis, pollinosis, digestive tract allergy, urticaria, hypersensitivity pneumonia, lung aspergillosis, eosinophil leukemia, parasite infection, eosinophilia, eosinophil pneumonia, eosinophil gastroenteritis, autoimmune disease, systemic lupus erythematosus, virus infection, bacteria infection, obesity, overeating (hyperphagia), malignant tumor, and acquired immunodeficiency syndrome (AIDS). Thus, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile was coupled with 6-[3-(4-fluorophenyl)-1-trityl-1H-pyrazolyl]-3-iodoimidazo[1,2-a]pyridine in the presence of tetrakis(triphenylphosphine)palladium and K3PO4 in DMF at 75° for 3 h followed by treating a solution of the coupling product in THF and MeOH with 5 N aqueous HCl to give 4-[6-[3-(4-fluorophenyl)-1H-4-pyrazolyl]imidazo[1,2-a]pyridin-3-yl]benzonitrile dihydrochloride (II). II showed IC50 of <10 nM for inhibiting the IL-4-induced induction of alkali phosphatase in human embryonic kidney cell transfected with STAT gene and STAT reporter gene.

IT 474695-81-33
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)
 RN 474695-81-3 CAPLUS
 CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[5-(methylsulfonyl)-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 474711-86-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)
 RN 474711-86-9 CAPLUS
 CN 1H-Benzimidazole, 6-bromo-1-[5-(methylsulfonyl)-2-thienyl]- (CA INDEX NAME)



RN 474711-86-9 CAPLUS
 CN 1H-Benzimidazole, 5-bromo-1-[5-(methylsulfonyl)-2-thienyl]- (CA INDEX NAME)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

X L6 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2002:716272 CAPLUS Full-text
 DN 137:232656
 TI Preparation of 5-(phenylheteroaryl)-1,3-dihydro-2-benzimidazolone MAP


kinase inhibitors as anti-inflammatory agents
 IN Dombroski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis
 PA Prizer Products Inc., USA
 SO PCT Int. Appl., 272 pp.
 CODEN: PIKX22
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002072576	A1	20020919	WO 2002-1B334	20020130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, ME, MO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440211	A1	20020919	CA 2002-2440211	20020130
AU 2002226639	A1	20020924	AU 2002-226639	20020130
EP 1370557	A1	20031217	EP 2002-716257	20020130
EP 1370557	B1	20051116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007957	A	20040225	BR 2002-7957	20020130
JP 2004526727	T	20040902	JP 2002-571492	20020130
AT 309997	T	20051215	AT 2002-716257	20020130
ES 2251582	T3	20060501	ES 2002-2716257	20020130
US 2003092749	A1	20030515	US 2002-94717	20020311
US 7056918	B2	20060606		
MX 2003PA08142	A	20031212	MX 2003-PA8142	20030909
PRAI US 2001-274791P	P	20010309		
WO 2002-1B334	W	20020130		

OS CASREACT 137:232656, MARPAT 137:232656
 GI

alkyl(amino)sulfonyl, alkylsulfamoyl, carbamoyl, acyl, carboxy, etc.; n = 0-5) were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, (3R)-(-)-1-benzyl-3-aminopyrrolidine was condensed with 1,3-diethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-carbaldehyde in the presence of MgSO4 in CH2Cl2. Addition of ((4-methylphenylsulfonyl)(m-tolyl)methyl)isocyanide to the 5-(benzylpyrrolidinyl)benzimidazolone using DMF and MP-carbonate gave the 5-(m-tolyl)imidazolyl derivative. Treatment with Pd/C and HCl in MeOH afforded (R)-II·HCl. All of the compds. of the invention that were tested had an IC50 < 10 μM in TNFα and MAPKAP in vitro assays and an ED50 < mg/kg in an in vivo TNFα assay. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion of ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).

IT 459194-73-6P, 3-Methyl-1-thiophen-3-yl-5-(5-(m-tolyl)-3H-imidazol-4-yl)-1,3-dihydrobenzimidazol-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-inflammatory agent; preparation of (phenylheteroaryl)benzimidazolone MAP kinase inhibitors as anti-inflammatory agents)
 RN 459194-73-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-3-methyl-5-[5-(3-methylphenyl)-1H-imidazol-4-yl]-1-(3-thienyl)- (9CI) (CA INDEX NAME)




X

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - MAYBE 103 NEXT NE - CHECK!

AN 2001:526062 CAPLUS Full-text
 DN 135:107328
 TI Preparation of 1,2-diarylbenzimidazolealkanoates and analogs for treatment of disorders mediated by microglia activation
 IN Kuhnke, Joachim; Halfbrodt, Wolfgang; Moening, Ursula
 PA Schering Aktiengesellschaft, Germany
 SO PCT Int. Appl., 141 pp.
 CODEN: PIKX22
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001051473	A1	20010719	WO 2001-EP334	20010112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				



AB Title compds. I [wherein Het = (un)substituted pyrrolol, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, Ph, heteroaryl, heterocyclyl; R3 = independently halo, (perhalo)alkyl, (perhalo)cycloalkyl, alkenyl, alkynyl, heterocyclyl(oxy), Ph, OH, (perhalo)alkoxy, OPh, alkylthio,

LV, MA, MD, MG, MX, MN, MM, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


CA 2396227 A1 20010719 CA 2001-2396227 20010112
 BR 2001007628 A 20021008 BR 2001-7628 20010112
 EP 1246808 A1 20021009 EP 2001-915133 20010112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

HU 2002004011 A2 20030528 HU 2002-4011 20010112
 JP 2003523961 T 20030812 JP 2001-551855 20010112
 EE 200200390 A 20031015 EE 2002-390 20010112
 NZ 519326 A 20050225 NZ 2001-519326 20010112
 AU 782993 B2 20050915 AU 2001-42332 20010112
 US 2002006948 A1 20020117 US 2001-759360 20010112
 US 7115645 B2 20061003
 IN 2002MN00672 A 20050304 IN 2002-MN672 20020524
 MX 2002PA05742 A 20020918 MX 2002-PA5742 20020610
 BG 106821 A 20030131 BG 2002-106821 20020613
 NO 2002003362 A 20020913 NO 2002-3362 20020712
 ZA 2002006470 A 20040219 ZA 2002-6470 20020813
 US 2006094770 A1 20060504 US 2005-299135 20051208
 US 2006205803 A1 20060914 US 2005-305521 20051216

PRAI DE 2000-10002898 A 20000114
 US 2000-178324P P 20000127
 WO 2001-EP334 W 20010112
 US 2001-759360 A3 20010116


OS MARPAT 135:107326
 GI




AE Title compds. [1; R = Z1R4; R1, R2 = (un)substituted (hetero)aryl; R3 = H, halo, substituted alkyl, alkoxy, etc.; R4 = CO2H, alkoxycarbonyl, CONH2, SO3H, etc.; Z = O, (alkyl)imino, acylimino; Z1 = (heteroatom-interrupted) alkyl(en)ylene, etc.] were prepared. Thus, I (R1 = R2 = Ph, R3 = H) (II; R = 6-OH) was etherified by BrCH2CO2CHMe3 to give II (R = 6-OCH2CO2CHMe3). Data for biol. activity of I were given.

IT 350233-60-2 CAPLUS
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,2-diarylbenzimidazolealkanoates and analogs for treatment of disorders mediated by microglia activation)

RN 350233-60-2 CAPLUS
 CN Hexanoic acid, 6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-5-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 350233-62-4 CAPLUS
 CN Hexanoic acid, 6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-6-yl]oxy]-, methyl ester (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

6	ANSWER 21 OF 36	CAPLUS	COPYRIGHT 2008 ACS on STN	MAYBE 103	NEXT NE
AN	2000:891563	CAPLUS	Full Text		
DN	134:42130				
TI	Benzimidazole derivatives as tyrosine kinase inhibitors				
IN	Bilodeau, Mark T.; Cunningham, April M.; Hungate, Randall W.; Koester, Timothy J.				
PA	Merck & Co., Inc., USA				
SD	U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 143,881, abandoned.				
	CODEN: USXXAM				
DT	Patent				
LA	English				
FAN.CNT	4				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6162804	A	20001219	US 1999-266331	19990311
PRAI	US 1997-60151P	P	19970926		
	US 1998-143881	B2	19980831		
OS	MARPAT 134:42130				
GI					




AE Benzimidazoles I [X = CH, N; R1 = (un)substituted Ph, thienyl, thiazolyl; R2, R3 = H, alkyl, aryl, cycloalkyl, OH, NO2, NH2, halo; R4 = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; R5 = H, alkyl, alkoxy, aryloxy, halo, NH2, NO2, etc.] were prepared as tyrosine kinase inhibitors. Thus, II was prepared in 6 steps starting from 4-bromo-1-fluoro-2-nitrobenzene and proceeding via 4-methoxy-2-nitro-N-phenyl-4-biphenylamine. The products were inhibitors of vascular endothelial growth factor (VEGF) and inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values of 150-650 nM.


IT 260258-26-2P 260258-28-2P 260258-30-2P
 260258-32-2P 260258-34-2P 260258-36-2P
 260258-38-2P 260258-40-2P 260258-42-2P
 260258-44-2P 260258-46-2P 260258-48-2P
 260258-50-2P 260258-52-2P 260258-54-2P
 260258-56-2P 260258-58-2P 260258-60-2P
 260258-62-2P 260258-64-2P 260258-66-2P
 260258-68-2P 260258-70-2P 260258-72-2P
 260258-74-2P 260258-76-2P 260258-78-2P
 260258-80-2P 260258-82-2P 260258-84-2P
 260258-86-2P 260258-88-2P 260258-90-2P
 260258-92-2P 260258-94-2P 260258-96-2P
 260258-98-2P 260258-100-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (benzimidazole derivs. as tyrosine kinase inhibitors)


RN 221636-30-2 CAPLUS
 CN 1H-Benzimidazole, 5-[4-[3-(1-piperidinyl)propyl]phenyl]-1-(3-thienyl)- (CA INDEX NAME)




RN 260258-26-2 CAPLUS
 CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-27-3 CAPLUS
 CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-28-4 CAPLUS
 CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-29-5 CAPLUS
 CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-30-8 CAPLUS
 CN 2(1H)-Pyridinone, 1-[1-methyl-3-piperidinylmethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-32-0 CAPLUS
 CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-




RN 260258-33-1 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-42-2 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-43-3 CAPLUS
CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-44-4 CAPLUS
CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)


RN 260258-50-2 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[2-(2-oxo-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl)ethyl]- (CA INDEX NAME)




RN 260258-60-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-61-5 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-62-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-63-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-45-5 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)





RN 260258-46-6 CAPLUS
CN 2(1H)-Pyridinone, 1-[(1-methyl-3-piperidinyl)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-48-8 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-49-9 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-64-8 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[(1-methyl-3-piperidinyl)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-66-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-67-1 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-77-3 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-78-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinylethyl)-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)




RN 260258-79-5 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinylethyl)-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)




RN 260258-82-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)




RN 260258-84-2 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[[1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)




RN 312959-33-4 CAPLUS
CN 2(1H)-Pyrimidinone, 5-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)



RN 312959-34-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)




RN 312959-35-6 CAPLUS
CN 1H-Benzimidazole, 1-(3-thienyl)- (CA INDEX NAME)




RE.CMT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN - MAYBE NEXT NE - CHECK!


AN 2000:215999 CAPLUS Full-text
DN 132:258111
TI Benzimidazoles, their preparation, hole-transporting materials, electroluminescent devices, and electrophotographic photoreceptors thereof
IN Ueda, Hideaki; Fujino, Yasumitsu; Furukawa, Keiichi
PA Minolta Camera Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKKXAP




RN 260258-88-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)



RN 260258-89-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)




RN 312959-29-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)



RN 312959-31-2 CAPLUS
CN 2(1H)-Pyrimidinone, 5-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (CA INDEX NAME)


DT Patent
LA Japanese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI JP 2000095766 A 20000404 JP 1998-269595 19980924
PRAI JP 1998-269595 19980924
OS MARPAT 132:258111
GI



AB The benzimidazole compds. are shown as I (A = arylene, heterocyclic ring which may be linked; Ar1, Ar2 = aryl, heterocyclic ring; R1, R2 = H, alkyl, alkoxy, halo) and are prepared by reacting benzimidazoles II (A, R1, R2 = same as above) with halogens Ar1X and Ar2X (Ar1, Ar2 = same as above; X = halo). The hole-transporting materials for the electrophotog. photoreceptors comprise I and show excellent durability. The electroluminescent devices have 21 layer containing I.

IT 252424-77-5
RL: TEM (Technical or engineered material use); USES (Uses)
(preparation of benzimidazole deriva. for hole-transporting materials and electroluminescent devices and electrophotog. photoreceptors thereof)

RN 262434-77-5 CAPLUS
CN 2-Thiophenamine, 5,5'-[oxybis(4,1-phenylene-1H-benzimidazole-2,1-diyl)]bis[N,N-diphenyl- (9CI) (CA INDEX NAME)





L6 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN - MAYBE 103 NEXT NE - CHECK!

AN 2000:161133 CAPLUS Full-text
DN 132:194377
TI Preparation of benzimidazoles and imidazo[4,5-b]pyridines as novel angiogenesis inhibitors
IN Bloddeau, Mark T.; Hungate, Randall W.; Cunningham, April M.; Koester, Timothy J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXX2


DT Patent
LA English
FAN.CHT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012089	A1	20000309	WO 1999-US5297	19990311
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2341409	A1	20000309	CA 1999-2341409	19990311
	AU 9930789	A1	20000321	AU 1999-30789	19990311
	AU 760020	B2	20030508		
	EP 1109555	A1	20010627	EP 1999-912408	19990311
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002523459	T	20020730	JP 2000-567206	19990311
	US 6465484	B1	20020105	US 2001-786004	20010228
PRAI	US 1998-143881	A	19980831		
	US 1997-60151P	P	19970926		
	WO 1999-US5297	W	19990311		
OS	MARPAT 132:194377				
GI					




AB The title compds. [I; X = N, CH; R1, R3 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.; R4, R5 = H, alkyl, cycloalkyl, etc.] which inhibit tyrosine kinase enzymes, and therefore useful in treating tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals, were prepared. E.g., a multi-step synthesis of the benzimidazole II was given. Compds. I inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 of 150-650 nM.


IT 221636-30-2P 221636-34-6P 260258-26-2P
260258-27-2P 260258-28-4P 260258-29-5P
260258-30-8P 260258-31-9P 260258-32-0P




RN 260258-28-4 CAPLUS
CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-29-5 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-30-8 CAPLUS
CN 2(1H)-Pyridinone, 1-[1-(1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-31-9 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-32-0 CAPLUS
CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-


260258-33-1P 260258-34-2P 260258-42-2P
260258-43-3P 260258-44-4P 260258-45-5P
260258-46-6P 260258-47-7P 260258-48-8P
260258-49-9P 260258-50-2P 260258-60-4P
260258-61-5P 260258-62-6P 260258-63-7P
260258-64-3P 260258-65-9P 260258-66-0P
260258-67-1P 260258-68-2P 260258-77-3P
260258-78-4P 260258-79-5P 260258-82-6P
260258-84-2P 260258-86-4P 260258-88-6P
260258-89-7P 260258-90-0P
RN 221636-30-2 CAPLUS
CN 1H-Benzimidazole, 5-[4-[3-(1-piperidinyl)propyl]phenyl]-1-(3-thienyl)- (CA INDEX NAME)



RN 221636-34-6 CAPLUS
CN 1H-Benzimidazole, 5-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-1-(3-thienyl)- (CA INDEX NAME)




RN 260258-26-2 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-27-3 CAPLUS
CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)


benzimidazol-5-yl)- (CA INDEX NAME)




RN 260258-33-1 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-34-2 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl]ethyl]- (CA INDEX NAME)




RN 260258-42-2 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-43-3 CAPLUS
CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-78-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-79-5 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-82-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-84-2 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[(1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-86-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-88-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 260258-89-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 260258-90-0 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[2-(2-oxo-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyrimidinyl)ethyl]- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN - DEFINITELY APPEARS TO BE
103 NEXT RE


AN 1999:748315 CAPLUS Full-text
DN 131:351330
TI Preparation of 1-phenylbenzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
IN Boschelli, Diane Harris; Denny, William Alexander; Doherty, Annette Marian; Hamby, James Marino; Khatana, Sonya Shah; Kramer, James Bernard; Palmer, Brian Desmond; Showalter, Howard Daniel Hollis
PA Warner-Lambert Company, USA
SO U.S., 25 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 5990146 A 19991123 US 1998-135470 19980817
US 6218388 B1 20010417 US 1999-459011 19991210
PRAI US 1997-56609P P 19970820
US 1998-135470 A3 19980817
US 1999-408630 A3 19990930
OS MARPAT 131:351330
GI



AB The title compds. [I; Ar = (un)substituted aryl; R1-R4 = H, alkyl, halo, etc.] and their pharmaceutically acceptable salts, inhibitors of protein tyrosine kinases such as FGFR and PDGFR which are useful in treating cellular proliferation, especially in treating cancer, atherosclerosis, restenosis, and psoriasis, were prepared. Thus, reduction of 1-(4-nitrophenyl)benzimidazole over Raney Ni in THF afforded 79% 1.2HCl [Ar = 4-H2NOC6H4; R1-R4 = H] which showed IC50 of > 10 μM against PDGFR-stimulated receptor autophosphorylation in rat aorta smooth muscle cells.
IT 756691-87-3P 266591-88-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of 1-phenylbenzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation)

RN 250691-87-3 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-1-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 250691-88-4 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-1-(3-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN - DEFINITELY CHECK

AN 1999:233907 CAPLUS Full-text
DN 130:252359
TI Preparation of benzimidazoles and imidazopyridines as tyrosine kinase inhibitors
IN Blodeau, Mark T.; Hungate, Randall W.; Cunningham, April M.; Koester, Timothy J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9916755 A1 19990408 WO 1998-US19789 19980922
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,


CM, GA, GN, GW, MJ, MR, NE, SN, TD, TG
 CA 2302830 A1 19990408 CA 1998-2303830 19980922
 AU 9835003 A 19990423 AU 1998-95003 19980922
 AU 744939 B2 20020307
 EP 1017662 A1 20000712 EP 1998-948427 19980922
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 SI, LT, LV, FI, RO
 JP 2001518470 T 20011016 JP 2000-513841 19980922
 PRA1 US 1997-60151P P 19970926
 GB 1998-10544 A 19980515
 WO 1998-US19789 W 19980922
 OS MARPAT 130:252359
 G1




AB The title compds. I [X = N, C; R1 = H, alkyl, cycloalkyl, halo, etc.; R2, R3 = H, alkyl, aryl, OH, etc.; R4 = H, alkyl, alkoxy, alkenyl, etc.; R5 = H, alkyl, halo, etc.], which inhibit tyrosine kinase enzymes, were prepared. E.g., 1-phenyl-5-(4-methoxyphenyl)benzimidazole was prepared.

IT 221636-20-6 CAPLUS
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzimidazoles and imidazopyridines as tyrosine kinase inhibitors)


RN 221636-20-6 CAPLUS
 CN 1H-Benzimidazole, 5-[4-[3-(1-piperidinyl)propyl]phenyl]-1-(3-thienyl)- (CA INDEX NAME)



RN 221636-34-6 CAPLUS
 CN 1H-Benzimidazole, 5-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-1-(3-thienyl)- (CA INDEX NAME)



RN 220495-91-1 CAPLUS
 CN 1H-Benzimidazole, 4-methoxy-1-(3-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN - DEFINITELY CHECK FOR 103! - THIS WAS MY PRIMARY REFERENCE IN PAOM - MAYBE CAN USE THIS TO 103 INSTEAD

AN 1998:789290 CAPLUS Full-text
 DN 130:177118
 TI Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor
 AU Palmer, Brian D.; Smail, Jeff B.; Boyd, Maruta; Boschelli, Dianne H.; Doherty, Annette M.; Hamby, James M.; Khatana, Sonya S.; Kramer, James B.; Kraker, Alan J.; Panek, Robert L.; Lu, Gina H.; Dahring, Tawny K.; Winters, R. Thomas; Showalter, H. D. Hollis; Denny, William A.
 CS Auckland Cancer Society Research Centre Faculty of Medicine and Health Sciences, The University of Auckland School of Medicine, Auckland, N. Z.
 SO Journal of Medicinal Chemistry (1998), 41(27), 5457-5465
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB 1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure-activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A systematic study of substituted 1-phenylbenzimidazoles showed clear SARs. Substituents at the 4'- and 3'-positions of the Ph ring are tolerated but do not significantly improve activity, while substituents at the 2'-position abolish it. Substituents in the 2-, 4-, and 7-positions of the benzimidazole ring (with the exception of 4-OH) also abolish activity. Most substituents at the 5- and 6-positions maintain or increase activity, with the 5-OH, 5-OMe, 5-COMe, and 5-CO2Me analogs being >10-fold more potent than the parent 1-phenylbenzimidazole. The 5-OMe analog was both the most potent inhibitor, and showed the highest selectivity (50-fold) between PDGFR and PGFR isolated enzymes, and also a moderately effective inhibitor (IC50 = 1.9 μM) of PDGF-stimulated PDGFR autophosphorylation in rat aorta smooth muscle cells.
 IT 220495-91-01 220495-91-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor)
 RN 220495-91-0 CAPLUS
 CN 1H-Benzimidazole, 4-methoxy-1-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

ONLY CHECKED TO SEE IF ELECTED SPECIES ALLOWABLE OVER
 REFERENCES 27-36

L6 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
 AN 1989:85282 CAPLUS Full-text
 DN 110:85282
 TI Electrophotographic photoreceptor containing charge-transporting benzimidazole derivative
 IN Shiino, Yasuko; Matsumoto, Masakazu
 PA Canon K. K., Japan
 SO Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKKXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
P1 JP 63157157	A	19880630	JP 1986-303856	19861222
PRA1 JP 1986-303856		19861222		


 G1



AB The title photoreceptor has a photosensitive layer containing a benzimidazole derivative I (R1 = alkyl, aryl, heterocyclyl; R2, R3 = H, R1, aralkyl; R2, R3, and the central C may form a ring residue; A = aralkyl, R1).


IT 119028-39-6
 RL: TEM (Technical or engineered material use); USES (Uses) (electrophotograph, charge-transporting agent)

RN 119028-39-6 CAPLUS
 CN Benzenamine, N,N-dimethyl-4-[1-(2-thienyl)-5-(9H-xanthen-9-ylidenemethyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)




L6 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2008 ACS ON STN
 AN 1988:562796 CAPLUS Full-text


DN 109:162796
 TI Determination of telenzepine in human serum by gas chromatography-mass spectrometry
 AU Sturm, E.; Junker, A.
 CS Byk Gulden Pharm., Konstanz, D-7750, Fed. Rep. Ger.
 SO Journal of Chromatography (1988), 430(1), 43-51
 CODEN: JOCRAM; ISSN: 0021-9673
 DT Journal
 LA English
 OS CASREACT 109:162796
 AB A method for determining telenzepine in human serum is described. Analytes are obtained from alkalized serum by extraction of the drug using reversed-phase octadecylsilane-bonded silica cartridges. Telenzepine and a demethyl analog added to serum as internal standard are retained on the C18 cartridge and recovered by elution with MeOH. The gas chromatog. properties of telenzepine and the internal standard are improved by a 2-step derivatization involving a benzodiazepinone-benzimidazole rearrangement and simultaneous formation of a Me ester function. The processed extract is analyzed by gas chromatog.-mass spectrometry with selected-ion monitoring. Quantification is linear over the range 2-40 ng/mL. Inter-day precision is within 7%, except at the detection limit of 2 ng/mL (16%). Application of this assay to routine anal. is limited by the extensive sample pretreatment essential for derivatization of telenzepine.
 IT 117019-16-6P 117019-17-7P 117019-18-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for telenzepine determination in human blood by gas chromatog.)
 RN 117019-16-6 CAPLUS
 CN 3-Thiophenecarboxylic acid, 5-methyl-4-[2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



RN 117019-17-7 CAPLUS
 CN 3-Thiophenecarboxylic acid, 4-[2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 113387-86-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-4-chloro-3-hydroxy-, methyl ester (CA INDEX NAME)



L6 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1988:131570 CAPLUS Full-text
 DN 108:131570
 TI Process for the preparation of 3-hydroxy-5-(1-polyazazolyl)-2-methoxycarbonylthiophenes, useful as pharmaceuticals or their intermediates
 IN Corral Saleta, Carlos; Lissavetzky Diez, Jaime
 PA Consejo Superior de Investigaciones Cientificas, Spain
 SO Span., 7 pp.
 CODEN: SPXXAD
 DT Patent
 LA Spanish
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 547442	A1	19861116	ES 1985-547442	19850930
PRAI ES 1985-547442		19850930		

 GI




AB The title compds. (I; X = H, halo; R = heterocyclic polyazolo or benzopolyazolo), useful as intermediate or final products in the synthesis of new therapeutic agents (no data), are prepared by condensation with chloro(methoxycarbonyl)oxodihydrothiophenes II with 2 equivalent polyazolo or benzopolyazolo RH at room temperature. A solution of 0.009 mol II (X = H) in HOAc was treated with 0.018 mol pyrazole and kept at room temperature for 2 days to give crystalline I (X = H, R = 1-pyrazolyl).
 IT 113387-85-2P 113387-86-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as drug and/or intermediate)
 RN 113387-85-2 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl


RN 117019-18-8 CAPLUS
 CN 3-Thiophenecarboxylic acid, 5-methyl-4-[2-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




L6 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1988:150195 CAPLUS Full-text
 DN 108:150195
 TI Reactions of methyl 3-hydroxythiophene-2-carboxylate. Part 4. Synthesis of methyl 5-azolyl-3-hydroxythiophene-2-carboxylates
 AU Corral, Carlos; El-Ashawy, Mahmoud B.; Lissavetzky, Jaime; Manzanares, Ignacio
 CS Inst. Quim. Med., CSIC, Madrid, 28006, Spain
 SO Journal of Heterocyclic Chemistry (1987), 24(5), 1301-3
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 108:150195
 GI




AB Oxodihydrothiophenes I (R1 = H, Cl) were treated with heterocycles, e.g., pyrazole, imidazole, benzotriazole to give thenoates II (R2 = 1-pyrazolyl, 1-imidazolyl, 1-benzotriazolyl, etc.).
 IT 113387-85-2P 113387-86-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 113387-85-2 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



ester (CA INDEX NAME)



RN 113387-86-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-4-chloro-3-hydroxy-, methyl ester (CA INDEX NAME)



L6 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1986:198778 CAPLUS Full-text
 DN 104:198778
 OREF 104:31269a,31272a
 TI Synthesis, structure, and interconversion of polypyrazolylborate complexes of molybdenum(V)
 AU Lincoln, Sandra; Koch, Stephen A.
 CS Dep. Phys. Life Sci., Univ. Portland, Portland, OR, 97203, USA
 SO Inorganic Chemistry (1986), 25(10), 1594-602
 CODEN: INOACJ; ISSN: 0020-1669
 DT Journal
 LA English
 AB HB(pz)3MoCl2 (I; pz = pyrazolyl) was prepared by the reaction of O2 with HB(pz)3MoCl3. Two HB(pz)3MoCl2O (II) geometric isomers and HB(pz)3)2Mo2O2(μ-O)2 (III) were obtained from the reaction of MoCl5 and HB(pz)3 in dilute HCl. Mo4(HB(pz)3)2(O)4(μ-O)4(μ-OMe)2(HOMe)2 (IV) was prepared from the reaction of III with MeOH. I, II, and IV were structurally characterized by x-ray diffraction. II have the structures typical of Mo2O34- dimers with linear Mo-O-Mo bridges; they provide the 1st example of Mo:Mo distortional isomers with a d1 electronic configuration: the Mo-oxo distance of 1.670(4) and 1.779(6) Å. The yellow-brown colors of II with intense bands at 21,045 cm-1 indicate that the previous interpretations of the electronic spectra of Mo2O34- complexes must be reevaluated. The chemical and crystallog. characterization of IV indicated that it is a Mo(V) tetramer with a zigzag chain of 4 Mo atoms. The importance of correctly distinguishing between a coordinated alkoxide and a coordinated alc. is demonstrated in the structure of IV and by the reformulation of 2 Mo(V) tetramers that had been previously reported in the literature as mixed-valence complexes.
 IT 101315-85-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reformulation of alkoxo complex as)
 RN 101315-85-9 CAPLUS


CN Molybdate(2-), tetrachlorobis(ethanol)di-μ-ethoxydi-μ-oxodi-μ3-oxotetraoxotetra-, (2Mo-Mo), stereoisomer, dihydrogen, compd. with 1,2-di-(2-thienyl)-1H-benzimidazole (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 101315-84-8

CMF C* H22 C14 Mo4 O12 . 2 H

CCI CCS




● 2 H⁺

CM 2

CRN 101315-83-7

CMF C15 H10 N2 S2



L6 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:156539 CAPLUS [Full-text](#)

DN 100:156539

OREF 100:23847a,23850a

TI Compounds with antiulcer and antisecretory activity. II.

3-Heteroaryl-benzimidazolin-2-ones

AU Bianchi, Mario; Butti, Alina; Rossi, Silvano; Barzaghi, Fernando;

Marcara, Viviana

CS Dep. Chem. Synth., Roussel-Maestretti S.p.A., Milan, Italy


SO European Journal of Medicinal Chemistry (1983), 18(6), 495-500

CODEN: EJMCAS; ISSN: 0009-4374

DT Journal

LA English

GI



AB Thienobenzodiazepines I (R = H, F) were prepared by sequential reaction of Et 2-amino-5-ethylthiophene-3-carboxylate with 2,5-F(R)C6H3NO2 II (R = H, F) in the presence of BuLi, catalytic reduction, and cyclization of the resulting amino esters III by 3 equiv NaCH2SOMe (70°, N). Thienobenzodiazepines IV and V were prepared analogously from reactions of Me 3-aminothiophene-2-carboxylate and Me 4-aminothiophene-3-carboxylate, resp., with II. An attempted cyclization of III (R = F) with 1 equiv NaCH2SOMe at 280° gave the rearranged benzimidazolone product VI.


IT 65092-66-2

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 69363-54-4 CAPLUS

CN 2H-Benzimidazol-2-one, 1-(5-ethyl-2-thienyl)-5-fluoro-1,3-dihydro- (CA INDEX NAME)



L6 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1978:37692 CAPLUS [Full-text](#)

DN 88:37692

OREF 88:5917a,5920a

TI Synthesis of microheterocycles: Part IV. Syntheses of 1-substituted

4-nitroindazoles, 5- and 6-nitroindazoles and 6-nitrobenzimidazoles

AU Arya, V. P.; Fernandes, F.; Honkan, V.; Ray, D. K.; Shrivastava, V. B.

CS Ciba-Geigy Res. Cent., Bombay, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including

Medicinal Chemistry (1977), 15B(7), 625-8


CODEN: IJSDDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 88:37692

GI



AB Benzimidazolones I (R = H, Me, Et, CHMe2; R1 = (un)substituted pyridyl, pyrazinyl, 2-pyrimidinyl, pyridazinyl, 2-quinolyl, 3-thienyl, 2-thiazolyl, 5-tetrazolyl, 5-methyl-1,2,4-oxadiazol-3-yl; R2 = H, 5-Cl, 6-Cl, 5-CF3) (24 compds.) were prepared by various methods. I (R = Me, R1 = pyrazinyl, R2 = 5-Cl) had the best antisecretory and antiulcer activity, but induced convulsions, vomiting, and diarrhea on repeated oral administration in dogs.


IT 65092-66-2

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and antiulcer and antisecretory activity of)

RN 89660-06-0 CAPLUS

CN 2H-Benzimidazol-2-one, 5-chloro-1,3-dihydro-1-methyl-3-(3-thienyl)- (CA INDEX NAME)



L6 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1979:121555 CAPLUS [Full-text](#)

DN 90:121555

OREF 90:19247a,19250a

TI Heteroarene fused benzodiazepines. Part 1. Synthesis of

thieno[2,3-b][1,5]-, -[3,2-b][1,5]-, and -[3,4-b][1,5]benzodiazepines

AU Chakrabarti, Jiban K.; Hicks, Terence A.; Holten, Terrence M.; Tupper,

David E.

CS Lilly Res. Cent., Windlesham, UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and

Bio-Organic Chemistry (1972-1999) (1978), (9), 937-41


CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English

OS CASREACT 90:121555

GI



AB 1-Chloro-4-nitroisquinoline (I) was treated with oxazolidin-2-one and thiazolidin-2-one in the presence of NaH to give II (X = O, S), resp. Reaction of I with H2NCH2CH(OMe)2 gives III which was cyclized to give IV. 5- and 6-nitroindazoles react with 2-halo-3- or 5-substituted-pyridines in the presence of NaH in DMF to yield 1-substituted 5- and 6-nitroindazoles (e.g., V). Similar reaction of 6-nitrobenzimidazole sodium salt with compds. containing reactive chlorine affords 1-substituted-6-nitrobenzimidazoles (e.g., VI). The prepared compds. possess no appreciable in vivo antibacterial, antifungal, antiamoebic or antiparasitic activity.


IT 65092-66-2

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 65092-66-2 CAPLUS

CN Thiophene-3-yl, tetrahydro-4-(6-nitro-1H-benzimidazol-1-yl)-, 1,1-dioxide (CA INDEX NAME)



L6 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1975:497232 CAPLUS [Full-text](#)

DN 83:97232

OREF 83:15277a,15280a

TI Synthesis of 4,9-dihydro-9-(2-dimethylaminoethyl)-4-methylthieno[3,4-

b][1,5]benzodiazepin-10-one, a benzodiazepine-analogous thiophene derivative


AU Hronak, Otto; Binder, Dieter; Eichinger, Karl

CS Inst. Org. Chem., Tech. Hochschule, Wien, Vienna, Austria


SO Monatshefte fuer Chemie (1975), 106(2), 375-9

CODEN: MOCMB7; ISSN: 0026-9247

DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB Condensation of o-C₆H₄(NH₂)₂ with thiophene I in boiling xylene gave 5% thienobenzimidazepinone II and 58% thienylbenzimidazolone III and IV. Decreasing the temperature by use of boiling toluene gave 46% II, but lower temps. did not give better yields. II was aromatized to V (R = R₁ = H), which was methylated to V (R = Me, R₁ = H) and then treated with Cl(CH₂)₂NMe₂ to give V (R = Me, R₁ = (CH₂)₂NMe₂).
IT 56276-54-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and desulfurization of)
RN 56276-54-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




IT 56276-55-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 56276-55-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(4,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




L6 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:497128 CAPLUS [Full-text](#)
DN 83:97128
OREF 83:15253a,15256a
TI Synthesis of 1,3-dihydro-3-(2-dimethylaminoethyl)-1-(3-thienyl)benzimidazol-2-ones
AU Hromatka, Otto; Binder, Dieter; Eichinger, Karl
CS Inst. Org. Chem., Tech. Hochsch. Wien, Vienna, Austria
SO Monatshefte fuer Chemie (1975), 106(2), 555-8
CODEN: MOCMB7; ISSN: 0026-9247
DT Journal
LA German
CS CASREACT 83:97128
GI For diagram(s), see printed CA Issue.
AB Benzimidazolone (I, R = H) (II) was prepared by condensation of o-(H₂N)2C₆H₄ with Me tetrahydro-4-oxo-3-thiophenecarboxylate. Amination of II by


Cl(CH₂)₂NMe₂ gave I (R = CH₂CH₂NMe₂). Dehydrogenation of II by chloranil gave benzimidazolone (III, R = X = H) which was aminated to give III (R = CH₂CH₂NMe₂, X = H). Addnl. obtained were III (R = H, CH₂CH₂NMe₂, X = Cl).
IT 56276-54-1P 56276-55-2P 56477-00-0P 56477-01-1P 56477-02-2P 56477-03-3P 56477-04-4P 56477-05-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 56276-54-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




RN 56276-55-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(4,5-dihydro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)




RN 56477-00-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-3-(2-(dimethylamino)ethyl)-1,3-dihydro- (CA INDEX NAME)




RN 56477-01-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-(3-thienyl)- (CA INDEX NAME)




RN 56477-02-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-1,3-dihydro- (CA INDEX NAME)



RN 56477-03-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-1,3-dihydro-3-(3-thienyl)- (CA INDEX NAME)




RN 56477-04-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-3-[2-(dimethylamino)ethyl]-1,3-dihydro- (CA INDEX NAME)



RN 56477-05-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-3-[2-(dimethylamino)ethyl]-1,3-dihydro-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CN 56477-04-4
CMF C15 H16 Cl N3 O 8



CM 2

CN 88-89-1
CMF C6 H3 N3 O7

